US20070049988A1 - Optimal electrode contact polarity configurations for implantable stimulation systems - Google Patents

Optimal electrode contact polarity configurations for implantable stimulation systems Download PDF

Info

Publication number
US20070049988A1
US20070049988A1 US11/322,788 US32278805A US2007049988A1 US 20070049988 A1 US20070049988 A1 US 20070049988A1 US 32278805 A US32278805 A US 32278805A US 2007049988 A1 US2007049988 A1 US 2007049988A1
Authority
US
United States
Prior art keywords
stimulation
polarity
electrode contact
stimulator
optimal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US11/322,788
Inventor
Rafael Carbunaru
Kristen Jaax
Todd Whitehurst
James Makous
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boston Scientific Neuromodulation Corp
Original Assignee
Advanced Bionics Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US11/280,582 priority Critical patent/US7702385B2/en
Priority to US11/280,620 priority patent/US7920915B2/en
Application filed by Advanced Bionics Corp filed Critical Advanced Bionics Corp
Priority to US11/322,788 priority patent/US20070049988A1/en
Priority to CA002626440A priority patent/CA2626440A1/en
Priority to PCT/US2006/044870 priority patent/WO2007059343A2/en
Priority to EP06844430A priority patent/EP1948292A4/en
Priority to AU2006315285A priority patent/AU2006315285B2/en
Publication of US20070049988A1 publication Critical patent/US20070049988A1/en
Assigned to ADVANCED BIONICS CORPORATION reassignment ADVANCED BIONICS CORPORATION ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: CARBUNARU, RAFAEL, WHITEHURST, TODD K., MAKOUS, JAMES C., JAAX, KRISTEN N.
Assigned to BOSTON SCIENTIFIC NEUROMODULATION CORPORATION reassignment BOSTON SCIENTIFIC NEUROMODULATION CORPORATION CHANGE OF NAME (SEE DOCUMENT FOR DETAILS). Assignors: ADVANCED BIONICS CORPORATION
Priority to US13/053,031 priority patent/US8630705B2/en
Priority to US14/102,388 priority patent/US20140100633A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00Electrotherapy; Circuits therefor
    • A61N1/02Details
    • A61N1/04Electrodes
    • A61N1/05Electrodes for implantation or insertion into the body, e.g. heart electrode
    • A61N1/0551Spinal or peripheral nerve electrodes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00Electrotherapy; Circuits therefor
    • A61N1/18Applying electric currents by contact electrodes
    • A61N1/32Applying electric currents by contact electrodes alternating or intermittent currents
    • A61N1/36Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
    • A61N1/372Arrangements in connection with the implantation of stimulators
    • A61N1/375Constructional arrangements, e.g. casings
    • A61N1/37518Anchoring of the implants, e.g. fixation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00Electrotherapy; Circuits therefor
    • A61N1/18Applying electric currents by contact electrodes
    • A61N1/32Applying electric currents by contact electrodes alternating or intermittent currents
    • A61N1/36Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
    • A61N1/3605Implantable neurostimulators for stimulating central or peripheral nerve system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00Electrotherapy; Circuits therefor
    • A61N1/18Applying electric currents by contact electrodes
    • A61N1/32Applying electric currents by contact electrodes alternating or intermittent currents
    • A61N1/36Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
    • A61N1/372Arrangements in connection with the implantation of stimulators
    • A61N1/37205Microstimulators, e.g. implantable through a cannula
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00Electrotherapy; Circuits therefor
    • A61N1/18Applying electric currents by contact electrodes
    • A61N1/32Applying electric currents by contact electrodes alternating or intermittent currents
    • A61N1/36Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
    • A61N1/372Arrangements in connection with the implantation of stimulators
    • A61N1/375Constructional arrangements, e.g. casings
    • A61N1/3756Casings with electrodes thereon, e.g. leadless stimulators

Definitions

  • Implantable stimulators typically stimulate internal tissue, such as a nerve, by emitting an electrical stimulation current according to programmed stimulation parameters.
  • Microstimulators are typically formed with a small, cylindrical housing containing electronic circuitry that produces the desired electric stimulation current between spaced electrodes. These stimulators are implanted proximate to the target tissue so that the stimulation current produced by the electrodes stimulates the target tissue to reduce symptoms or otherwise provide therapy for a wide variety of conditions and disorders. Exemplary microstimulators are described in U.S. Pat. Nos. 5,312,439; 5,193,539; 5,193,540; and 5,405,367; 6,185,452; and 6,214,032. All of these listed patents are incorporated by reference in their respective entireties.
  • IPG implantable pulse generator
  • a typical IPG includes a multi-channel pulse generator housed in a rounded titanium case.
  • the IPG is generally coupled to a lead with a number of electrodes disposed thereon. Stimulation current is generated by the IPG and delivered to target tissue via the electrodes on the lead.
  • Exemplary IPGs are described in U.S. Pat. Nos. 6,381,496; 6,553,263; and 6,760,626. All of these listed patents are incorporated by reference in their respective entireties.
  • a key part of patient treatment using an implanted stimulator is the proper placement of the stimulator such that the stimulation electrodes are proximate to the stimulation site to be stimulated. If the stimulation electrodes are optimally placed near the stimulation site, stimulation can be affected over a wide range of parameters and power consumption can be minimized. However, optimal placement of a stimulator within a patient is often difficult to accomplish.
  • Systems for treating a patient with a medical condition include a lead having an array of electrode contacts each being programmable to have either a first polarity or a second polarity and a programming device configured to test a multiplicity of different electrode contact polarity configurations in which a programmed polarity of one or more of the electrode contacts is varied.
  • Methods of using an implantable stimulator system include implanting a lead having an array of programmable electrode contacts disposed thereon in communication with a stimulation site, testing a multiplicity of different electrode contact polarity configurations in which a programmed polarity of one or more of the electrode contacts is varied, selecting an optimal electrode contact polarity configuration out of the multiplicity of different electrode contact polarity configurations, and applying the stimulation current via the optimal electrode contact polarity configuration to the stimulation site in accordance with one or more stimulation parameters.
  • FIG. 1A depicts the upper cervical spine area of a patient and shows a number of nerves originating in the upper cervical spine area.
  • FIG. 1B shows various nerves in the back of the head and neck.
  • FIG. 1C illustrates a view of the major nerves and arteries in the human head as viewed from above looking down on the top or superior part of the head.
  • FIGS. 1D and 1E depict the trigeminal nerve and its branches.
  • FIG. 2 illustrates an exemplary stimulator that may be used to apply a stimulus to a target nerve to treat a particular medical condition according to principles described herein.
  • FIG. 3 illustrates an exemplary microstimulator that may be used as the stimulator according to principles described herein.
  • FIG. 4 depicts a number of stimulators configured to communicate with each other and/or with one or more external devices according to principles described herein.
  • FIGS. 5A-5H illustrate a number of exemplary electrode contact arrangements that may be a part of a stimulating lead that is used to apply a stimulation at one or more stimulation sites within a patient according to principles described herein.
  • FIG. 6 is a graph illustrating the relative current threshold values of monopolar, bipolar, and tripolar electrode configurations as a function of distance from the stimulation site according to principles described herein.
  • FIG. 7 is a flow chart illustrating an exemplary method of current steering that may be used to determine the optimal stimulation parameters for a patient according to principles described herein.
  • FIGS. 8A-8C illustrate an exemplary method of current steering according to principles described herein.
  • a lead with an array of electrode contacts is implanted in communication with a stimulation site.
  • the lead is coupled at a proximal end to an implantable stimulator that is configured to generate a stimulus, such as an electrical stimulation current.
  • a stimulus such as an electrical stimulation current.
  • Each of the electrode contacts of the array may be selectively programmed to function as an anode or cathode.
  • Current steering methods are then used to test a multiplicity of different electrode contact polarity configurations and select an optimal electrode contact polarity configuration for applying the stimulus to a stimulation site within the patient.
  • FIG. 1A depicts the upper cervical spine area (C 1 -C 4 ) of a patient.
  • a number of nerves arise from the upper cervical spine area (C 1 -C 4 ). Examples of such nerves include, but are not limited to, the greater occipital nerve(s)
  • FIG. 1B depicts the occipital nerves ( 130 ) in the back or posterior portion of the head and upper neck area of a patient.
  • the occipital nerves ( 130 ) are divided into greater ( 132 ) and lesser ( 134 ) occipital nerves.
  • the occipital nerves ( 130 ) lie subcutaneously in the posterior of the head and upper neck and are therefore relatively easily accessed.
  • a stimulator and/or electrode lead may be implanted in the posterior of the head or in the upper neck area of a patient to provide a stimulus to the occipital nerves ( 130 ).
  • FIG. 1C illustrates a view of the major nerves and arteries in the human head as viewed from above looking down on the top or superior part of the head.
  • the greater occipital nerves ( 132 ) extend to and across some of the top or superior portion of the head.
  • the lesser occipital nerves ( 134 ) may also extend to or near the top or superior portion of the head. Consequently, an implanted stimulator or an electrode lead may be positioned along the posterior part of the head or on the superior portion of the head and still provide a stimulus to the occipital nerves ( 130 ).
  • FIGS. 1D and 1E depict the trigeminal nerve ( 100 ) and its branches.
  • the trigeminal nerve ( 100 ) and its branches are responsible, in part, for the perception of head pain, including headaches and facial pain.
  • the trigeminal nerve ( 100 ) on each side of the head arises from a trigeminal ganglion ( 102 ), which lies within the skull in an area known as Meckel's cave ( 110 ). Access to either trigeminal ganglion ( 102 ) may be achieved via the foramen ovale ( 112 ) or the foramen rotundum ( 114 ).
  • This may provide a mechanism for selective stimulation of the sensory cells via appropriate placement of a stimulator for stimulation of one or both trigeminal ganglia ( 102 ).
  • FIGS. 1D and 1E also show a number of braches of the trigeminal nerve ( 100 ) including, but not limited to, the ophthalmic nerve ( 120 ), the maxillary nerve ( 122 ), and the mandibular nerve ( 124 ).
  • the supraorbital nerve (not shown) is also a branch of the trigeminal nerve ( 100 ).
  • the ophthalmic nerve ( 120 ) and the maxillary nerve ( 122 ) are entirely sensory, and sufficiently separate to allow independent and selective stimulation via appropriate placement of a stimulator.
  • the mandibular nerve ( 124 ) is both sensory and motor.
  • the mandibular nerve ( 124 ) innervates several facial muscles, including the muscles of mastication and the tensor tympani, which reflexively damps down the vibrations of the malleus by increasing the tension in the tympanic membrane.
  • the mandibular nerve ( 124 ) splits into a purely sensory branch that innervates the superior part of the lower jaw.
  • another branch splits into a purely sensory branch that innervates the inferior part of the lower jaw.
  • These branches may be sufficiently separate to allow independent and selective stimulation via appropriate placement of a stimulator.
  • a stimulator may be implanted in a patient to deliver an electrical stimulation current to one or more of the nerves in the head, particularly the occipital nerves ( 130 ).
  • This stimulation may be effective to treat headache pain (including, but not limited to chronic migraine headaches) and other types of pain or medical conditions, such as occipital neuralgia, facial pain, Bells palsy, etc.
  • the stimulator may additionally or alternatively be implanted in any site within the body and configured to treat any other medical condition such as, but not limited to, incontinence, peripheral nerve damage, sexual dysfunction, etc.
  • the term “stimulator” will be used broadly to refer any device that delivers a stimulus, such as an electrical stimulation current, one or more drugs or other chemical stimulation, thermal stimulation, electromagnetic stimulation, mechanical stimulation, and/or any other suitable stimulation at a stimulation site.
  • a stimulus such as an electrical stimulation current, one or more drugs or other chemical stimulation, thermal stimulation, electromagnetic stimulation, mechanical stimulation, and/or any other suitable stimulation at a stimulation site.
  • the term “stimulator” includes, but is not limited to, a stimulator, microstimulator, implantable pulse generator (IPG), system control unit (stimulator) or similar device.
  • the stimulation site referred to herein may include any nerve, tissue, blood vessel, or other area within the patient.
  • the stimulation site may include one or more of the following nerves: any cranial nerve; the greater, lesser or third occipital nerves; the trigeminal nerve; the infraorbital nerve; the facial nerve; the maxillary nerve, the mandibular nerve and divisions of those nerves such as the two branches of the ophthalmic division of the trigeminal nerve, i.e., the supratrochlear and supraorbital nerves; the zygomaticotemporal nerve branching from the maxillary division of the trigeminal nerve; the auriculotemporal nerve branching from the mandibular division of the trigeminal nerve; the pudendal nerve; and the cavernous nerve.
  • the stimulation site may additionally or alternatively include the cortex, spinal cord, or any other area of the central nervous system.
  • the stimulation site may include two or more stimulation sites, e.g.,
  • FIG. 2 illustrates an exemplary stimulator ( 140 ) that may be implanted within a patient ( 150 ) and used to apply a stimulus to a stimulation site, e.g., an electrical stimulation of the stimulation site, an infusion of one or more drugs at the stimulation site, or both.
  • a stimulation site e.g., an electrical stimulation of the stimulation site, an infusion of one or more drugs at the stimulation site, or both.
  • the electrical stimulation function of the stimulator ( 140 ) will be described first, followed by an explanation of the possible drug delivery function of the stimulator ( 140 ). It will be understood, however, that the stimulator ( 140 ) may be configured to provide only electrical stimulation, only a drug stimulation, both types of stimulation or any other type of stimulation as best suits a particular patient.
  • the exemplary stimulator ( 140 ) shown in FIG. 2 is configured to provide electrical stimulation at a stimulation site within a patient and includes a lead ( 141 ) having a proximal end coupled to the body of the stimulator ( 140 ).
  • a distal end of the lead ( 141 ) may be formed as a flat enlarged surface ( 162 ), referred to herein as a paddle, and implanted such that it is in communication with a stimulation site.
  • the term “in communication with” refers to the lead ( 141 ) or other device being adjacent, in the general vicinity, in close proximity, directly next to, or directly on the stimulation site such that a desired stimulation can be effectively delivered.
  • a number of electrodes ( 142 ) may be disposed on the paddle ( 162 ), as illustrated in FIG. 2 .
  • the electrodes ( 142 ) may be arranged on the paddle ( 162 ) in a variety of different possible configurations. As will be described in more detail below, the electrodes ( 142 ) are configured to apply an electrical stimulation current to the stimulation site as best suits a particular application.
  • the stimulator ( 140 ) includes a number of components. It will be recognized that the stimulator ( 140 ) may include additional and/or alternative components as best serves a particular application.
  • a power source ( 145 ) is configured to output voltage used to supply the various components within the stimulator ( 140 ) with power and/or to generate the power used for electrical stimulation.
  • the power source ( 145 ) may be a primary battery, a rechargeable battery, super capacitor, a nuclear battery, a mechanical resonator, an infrared collector (receiving, e.g., infrared energy through the skin), a thermally-powered energy source (where, e.g., memory-shaped alloys exposed to a minimal temperature difference generate power), a flexural powered energy source (where a flexible section subject to flexural forces is part of the stimulator), a bioenergy power source (where a chemical reaction provides an energy source), a fuel cell, a bioelectrical cell (where two or more electrodes use tissue-generated potentials and currents to capture energy and convert it to useable power), an osmotic pressure pump (where mechanical energy is generated due to fluid ingress), or the like.
  • the stimulator ( 140 ) may include one or more components configured to receive power from another medical device that is implanted within the patient.
  • the power source ( 145 ) When the power source ( 145 ) is a battery, it may be a lithium-ion battery or other suitable type of battery. When the power source ( 145 ) is a rechargeable battery, it may be recharged from an external system through a power link such as a radio frequency (RF) power link.
  • RF radio frequency
  • One type of rechargeable battery that may be used is described in International Publication WO 01/82398 A1, published Nov. 1, 2001, and/or WO 03/005465 A1, published Jan. 16, 2003, both of which are incorporated herein by reference in their respective entireties.
  • Other battery construction techniques that may be used to make a power source ( 145 ) include those shown, e.g., in U.S. Pat. Nos. 6,280,873; 6,458,171, and U.S. Publications 2001/0046625 A1 and 2001/0053476 A1, all of which are incorporated herein by reference in their respective entireties. Recharging can be performed using an external
  • the stimulator ( 140 ) may also include a coil ( 148 ) configured to receive and/or emit a magnetic field (also referred to as a radio frequency (RF) field) that is used to communicate with, or receive power from, one or more external devices ( 151 , 153 , 155 ).
  • a magnetic field also referred to as a radio frequency (RF) field
  • Such communication and/or power transfer may include, but is not limited to, transcutaneously receiving data from the external device, transmitting data to the external device, and/or receiving power used to recharge the power source ( 145 ).
  • an external battery charging system ( 151 ) may provide power used to recharge the power source ( 145 ) via an RF link ( 152 ).
  • External devices including, but not limited to, a hand held programmer (HHP) ( 155 ), clinician programming system (CPS) ( 157 ), and/or a manufacturing and diagnostic system (MDS)
  • 153 may be configured to activate, deactivate, program, and test the stimulator ( 140 ) via one or more RF links ( 154 , 156 ).
  • the links which are RF links ( 152 , 154 , 156 ) in the illustrated example, may be any type of link used to transmit data or energy, such as an optical link, a thermal link, or any other energy-coupling link.
  • One or more of these external devices ( 153 , 155 , 157 ) may also be used to control the infusion of one or more drugs into the stimulation site.
  • the CPS ( 157 ) may communicate with the HHP ( 155 ) via an infrared (IR) link ( 158 ), with the MDS ( 153 ) via an IR link ( 161 ), and/or directly with the stimulator ( 140 ) via an RF link ( 160 ).
  • these communication links ( 158 , 161 , 160 ) are not necessarily limited to IR and RF links and may include any other type of communication link.
  • the MDS ( 153 ) may communicate with the HHP ( 155 ) via an IR link ( 159 ) or via any other suitable communication link.
  • the HHP ( 155 ), MDS ( 153 ), CPS ( 157 ), and EBCS ( 151 ) are merely illustrative of the many different external devices that may be used in connection with the stimulator ( 140 ). Furthermore, it will be recognized that the functions performed by any two or more of the HHP ( 155 ), MDS ( 153 ), CPS ( 157 ), and EBCS ( 151 ) may be performed by a single external device.
  • One or more of the external devices ( 153 , 155 , 157 ) may be embedded in a seat cushion, mattress cover, pillow, garment, belt, strap, pouch, or the like so as to be positioned near the implanted stimulator ( 140 ) when in use.
  • the stimulator ( 140 ) may also include electrical circuitry ( 144 ) configured to produce electrical stimulation pulses that are delivered to the stimulation site via the electrodes ( 142 ).
  • the stimulator ( 140 ) may be configured to produce monopolar stimulation.
  • the stimulator ( 140 ) may alternatively or additionally be configured to produce multipolar stimulation including, but not limited to, bipolar or tripolar stimulation.
  • the electrical circuitry ( 144 ) may include one or more processors configured to decode stimulation parameters and generate the stimulation pulses.
  • the stimulator ( 140 ) has at least four channels and drives up to sixteen electrodes or more.
  • the electrical circuitry ( 144 ) may include additional circuitry such as capacitors, integrated circuits, resistors, coils, and the like configured to perform a variety of functions as best serves a particular application.
  • the stimulator ( 140 ) may also include a programmable memory unit ( 146 ) for storing one or more sets of data and/or stimulation parameters.
  • the stimulation parameters may include, but are not limited to, electrical stimulation parameters, drug stimulation parameters, and other types of stimulation parameters.
  • the programmable memory ( 146 ) allows a patient, clinician, or other user of the stimulator ( 140 ) to adjust the stimulation parameters such that the stimulation applied by the stimulator ( 140 ) is safe and efficacious for treatment of a particular patient.
  • the different types of stimulation parameters e.g., electrical stimulation parameters and drug stimulation parameters
  • the different types of stimulation parameters may be controlled independently. However, in some instances, the different types of stimulation parameters are coupled. For example, electrical stimulation may be programmed to occur only during drug stimulation or vice versa.
  • the programmable memory ( 146 ) may be any type of memory unit such as, but not limited to, random access memory (RAM), static RAM (SRAM), a hard drive, or the like.
  • the electrical stimulation parameters may control various parameters of the stimulation current applied to a stimulation site including, but not limited to, the frequency, pulse width, amplitude, electrode configuration (i.e., anode-cathode assignment), burst pattern (e.g., burst on time and burst off time), duty cycle or burst repeat interval, ramp on time, and ramp off time of the stimulation current that is applied to the stimulation site.
  • the drug stimulation parameters may control various parameters including, but not limited to, the amount of drugs infused at the stimulation site, the rate of drug infusion, and the frequency of drug infusion.
  • the drug stimulation parameters may cause the drug infusion rate to be intermittent, constant, or bolus.
  • Other stimulation parameters that characterize other classes of stimuli are possible.
  • the stimulation parameters may characterize the intensity, wavelength, and timing of the electromagnetic radiation stimuli.
  • the stimulation parameters may characterize the pressure, displacement, frequency, and timing of the mechanical stimuli.
  • Specific stimulation parameters may have different effects on different types of medical conditions.
  • the stimulation parameters may be adjusted by the patient, a clinician, or other user of the stimulator ( 140 ) as best serves a particular medical condition.
  • the stimulation parameters may also be automatically adjusted by the stimulator ( 140 ), as will be described below.
  • the amplitude of the stimulus current applied to a stimulation site may be adjusted to have a relatively low value so as to target relatively large diameter fibers of the stimulation site.
  • the stimulator ( 140 ) may also, or alternatively, increase excitement of a stimulation site by applying a stimulation current having a relatively low frequency (e.g., less than 100 Hz) to the stimulation site.
  • the stimulator ( 140 ) may also decrease excitement of a stimulation site by applying a relatively high frequency (e.g., greater than 100 Hz) to the stimulation site.
  • the stimulator ( 140 ) may also, or alternatively, be programmed to apply the stimulation current to a stimulation site intermittently or continuously.
  • the exemplary stimulator ( 140 ) shown in FIG. 2 is configured to provide drug stimulation to a patient, for example, a headache patient, by applying one or more drugs to a stimulation site.
  • a pump ( 147 ) may also be included within the stimulator ( 140 ).
  • the pump ( 147 ) is configured to store and dispense one or more drugs, for example, through a catheter ( 143 ).
  • the catheter ( 143 ) is coupled at a proximal end to the stimulator ( 140 ) and may have an infusion outlet ( 149 ) for infusing dosages of the one or more drugs at the stimulation site.
  • the stimulator ( 140 ) may include multiple catheters ( 143 ) and/or pumps ( 147 ) for storing and infusing dosages of the one or more drugs at the stimulation site.
  • the pump ( 147 ) or controlled drug release device described herein may include any of a variety of different drug delivery systems. Controlled drug release devices based upon a mechanical or electromechanical infusion pump may be used.
  • the controlled drug release device can include a diffusion-based delivery system, e.g., erosion-based delivery systems (e.g., polymer-impregnated with drug placed within a drug-impermeable reservoir in communication with the drug delivery conduit of a catheter), electrodiffusion systems, and the like.
  • a convective drug delivery system e.g., systems based upon electroosmosis, vapor pressure pumps, electrolytic pumps, effervescent pumps, piezoelectric pumps and osmotic pumps.
  • a micro-drug pump is another example.
  • Exemplary pumps ( 147 ) or controlled drug release devices suitable for use as described herein include, but are not necessarily limited to, those disclosed in U.S. Pat. Nos. 3,760,984; 3,845,770; 3,916,899; 3,923,426; 3,987,790; 3,995,631; 3,916,899; 4,016,880; 4,036,228; 4,111,202; 4,111,203; 4,203,440; 4,203,442; 4,210,139; 4,327,725; 4,360,019; 4,487,603; 4,627,850; 4,692,147; 4,725,852; 4,865,845; 5,057,318; 5,059,423; 5,112,614; 5,137,727; 5,234,692; 5,234,693; 5,728,396; 6,368,315 and the like.
  • Additional exemplary drug pumps suitable for use as described herein include, but are not necessarily limited to, those disclosed in U.S. Pat. Nos. 4,562,751; 4,678,408; 4,685,903; 5,080,653; 5,097,122; 6,740,072; and 6,770,067.
  • Exemplary micro-drug pumps suitable for use as described herein include, but are not necessarily limited to, those disclosed in U.S. Pat. Nos. 5,234,692; 5,234,693; 5,728,396; 6,368,315; 6,666,845; and 6,620,151. All of these listed patents are incorporated herein by reference in their respective entireties.
  • the stimulator ( 140 ) of FIG. 2 is illustrative of many types of stimulators that may be used to apply a stimulus to a stimulation site to treat headaches and other medical conditions.
  • the stimulator ( 140 ) may include an implantable pulse generator (EPG) coupled to one or more leads having a number of electrodes, a spinal cord stimulator (SCS), a cochlear implant, a deep brain stimulator, a drug pump (mentioned previously), a micro-drug pump (mentioned previously), or any other type of implantable stimulator configured to deliver a stimulus at a stimulation site within a patient.
  • EPG implantable pulse generator
  • SCS spinal cord stimulator
  • cochlear implant a deep brain stimulator
  • a drug pump mentioned previously
  • micro-drug pump micro-drug pump
  • Exemplary spinal cord stimulators suitable for use as described herein include, but are not limited to, those disclosed in U.S. Pat. Nos. 5,501,703; 6,487,446; and 6,516,227.
  • Exemplary cochlear implants suitable for use as described herein include, but are not limited to, those disclosed in U.S. Pat. Nos. 6,219,580; 6,272,382; and 6,308,101.
  • Exemplary deep brain stimulators suitable for use as described herein include, but are not limited to, those disclosed in U.S. Pat. Nos. 5,938,688; 6,016,449; and 6,539,263. All of these listed patents are incorporated herein by reference in their respective entireties.
  • the stimulator ( 140 ) may include an implantable microstimulator, such as a BION® microstimulator (Advanced Bionics® Corporation, Valencia, Calif.).
  • an implantable microstimulator such as a BION® microstimulator (Advanced Bionics® Corporation, Valencia, Calif.).
  • BION® microstimulator Advanced Bionics® Corporation, Valencia, Calif.
  • Various details associated with the manufacture, operation, and use of implantable microstimulators are disclosed in U.S. Pat. Nos. 5,193,539; 5,193,540; 5,312,439; 6,185,452; 6,164,284; 6,208,894; and 6,051,017. All of these listed patents are incorporated herein by reference in their respective entireties.
  • FIG. 3 illustrates an exemplary microstimulator ( 200 ) that may be used as the stimulator ( 140 ; FIG. 2 ) described herein.
  • Other configurations of the microstimulator ( 200 ) are possible, as shown in the above-referenced patents and as described further below.
  • the microstimulator ( 200 ) may include the power source ( 145 ), the programmable memory ( 146 ), the electrical circuitry ( 144 ), and the pump ( 147 ) described in connection with FIG. 2 . These components are housed within a capsule ( 202 ).
  • the capsule ( 202 ) may be a thin, elongated cylinder or any other shape as best serves a particular application.
  • the shape of the capsule ( 202 ) may be determined by the structure of the desired target nerve, the surrounding area, and the method of implantation.
  • the volume of the capsule ( 202 ) is substantially equal to or less than three cubic centimeters.
  • the microstimulator ( 200 ) may include two or more leadless electrodes ( 142 ) disposed on the outer surface of the microstimulator ( 200 ).
  • the external surfaces of the microstimulator ( 200 ) may advantageously be composed of biocompatible materials.
  • the capsule ( 202 ) may be made of glass, ceramic, metal, or any other material that provides a hermetic package that will exclude water vapor but permit passage of electromagnetic fields used to transmit data and/or power.
  • the electrodes ( 142 ) may be made of a noble or refractory metal or compound, such as platinum, iridium, tantalum, titanium, titanium nitride, niobium or alloys of any of these, in order to avoid corrosion or electrolysis which could damage the surrounding tissues and the device.
  • the microstimulator ( 200 ) may also include one or more infusion outlets ( 201 ).
  • the infusion outlets ( 201 ) facilitate the infusion of one or more drugs at a treatment site to treat a particular medical condition.
  • the infusion outlets ( 201 ) may dispense one or more drugs directly to the treatment site.
  • catheters may be coupled to the infusion outlets ( 201 ) to deliver the drug therapy to a treatment site some distance from the body of the microstimulator ( 200 ).
  • the stimulator ( 200 ) of FIG. 3 also includes electrodes ( 142 - 1 and 142 - 2 ) at either end of the capsule ( 202 ).
  • One of the electrodes ( 142 ) may be designated as a stimulating electrode to be placed close to the treatment site and one of the electrodes ( 142 ) may be designated as an indifferent electrode used to complete a stimulation circuit.
  • the microstimulator ( 200 ) may be implanted within a patient with a surgical tool such as a hypodermic needle, bore needle, or any other tool specially designed for the purpose. Alternatively, the microstimulator ( 200 ) may be implanted using endoscopic or laparoscopic techniques.
  • a stimulator may be configured to operate independently.
  • the stimulator ( 140 ) may be configured to operate in a coordinated manner with one or more additional stimulators, other implanted devices, or other devices external to the patient's body.
  • a first stimulator may control, or operate under the control of, a second stimulator, other implanted device, or other device external to the patient's body.
  • the stimulator ( 140 ) may be configured to communicate with other implanted stimulators, other implanted devices, or other devices external to the patient's body via an RF link, an untrasonic link, an optical link, or any other type of communication link.
  • the stimulator ( 140 ) may be configured to communicate with an external remote control unit that is capable of sending commands and/or data to the stimulator ( 140 ) and that is configured to receive commands and/or data from the stimulator ( 140 ).
  • various indicators of the medical condition and/or a patient's response to treatment may be sensed or measured. These indicators include, but are not limited to, electrical activity of the brain (e.g., EEG); neurotransmitter levels; hormone levels; metabolic activity in the brain; blood flow rate in the head, neck or other areas of the body; medication levels within the patient; patient input, e.g. when prodromal symptoms are sensed the patient can push a button on a remote control or other external unit; temperature of tissue in the stimulation target region, including the occipital nerve; physical activity level, e.g.
  • the stimulator ( 140 ) may be configured to change the stimulation parameters in a closed loop manner in response to these measurements.
  • the stimulator ( 140 ) may be configured to perform the measurements.
  • other sensing devices may be configured to perform the measurements and transmit the measured values to the stimulator ( 140 ).
  • Exemplary sensing devices include, but are not limited to, chemical sensors, electrodes, optical sensors, mechanical (e.g., motion, pressure) sensors, and temperature sensors.
  • one or more external devices may be provided to interact with the stimulator ( 140 ), and may be used to accomplish at least one or more of the following functions:
  • Function 1 If necessary, transmit electrical power to the stimulator ( 140 ) in order to power the stimulator ( 140 ) and/or recharge the power source ( 145 ).
  • Function 2 Transmit data to the stimulator ( 140 ) in order to change the stimulation parameters used by the stimulator ( 140 ).
  • Function 3 Receive data indicating the state of the stimulator ( 140 ) (e.g., battery level, drug level, stimulation parameters, etc.).
  • Additional functions may include adjusting the stimulation parameters based on information sensed by the stimulator ( 140 ) or by other sensing devices.
  • an exemplary method of treating a patient with a medical condition may be carried out according to the following sequence of procedures. The steps listed below may be modified, reordered, and/or added to as best serves a particular application.
  • a stimulator ( 140 ) is implanted so that its electrodes ( 142 ) and/or infusion outlet ( 149 ) are coupled to or located near a stimulation site (e.g., the occipital nerves or other nerves in the patient's head). If the stimulator ( 140 ) is a microstimulator, such as the microstimulator ( 200 ) described in FIG. 3 , the microstimulator itself may be coupled to the stimulation site.
  • the stimulator ( 140 ) is programmed to apply at least one stimulus to the stimulation site.
  • the stimulus may include electrical stimulation, drug stimulation, chemical stimulation, thermal stimulation, electromagnetic stimulation, mechanical stimulation, and/or any other suitable stimulation.
  • the patient When the patient desires to invoke stimulation, the patient sends a command to the stimulator ( 140 ) (e.g., via a remote control) such that the stimulator ( 140 ) delivers the prescribed stimulation.
  • the stimulator ( 140 ) may be alternatively or additionally configured to automatically apply the stimulation in response to sensed indicators of the medical condition.
  • the patient may turn off the stimulator ( 140 ) (e.g., via a remote control).
  • the power source ( 145 ) of the stimulator ( 140 ) is recharged, if necessary, in accordance with Function 1 described above. As will be described below, this recharging function can be made much more efficient using the principles disclosed herein.
  • the treatment administered by the stimulator ( 140 ), i.e., drug therapy and/or electrical stimulation, may be automatic and not controlled or invoked by the patient.
  • the implanted and/or external components may be desirable to modify or adjust the algorithmic functions performed by the implanted and/or external components, as well as the surgical approaches.
  • a first stimulator ( 140 ) implanted beneath the skin of the patient ( 208 ) provides a stimulus to a first location; a second stimulator ( 140 ′) provides a stimulus to a second location; and a third stimulator ( 140 ′′) provides a stimulus to a third location.
  • the implanted devices may operate independently or may operate in a coordinated manner with other implanted devices or other devices external to the patient's body. That is, an external controller ( 250 ) may be configured to control the operation of each of the implanted devices ( 140 , 140 ′, and 140 ′′).
  • an implanted device e.g.
  • stimulator ( 140 ) may control, or operate under the control of, another implanted device(s), e.g. stimulator ( 140 ′) and/or stimulator ( 140 ′′).
  • Control lines ( 262 - 267 ) have been drawn in FIG. 4 to illustrate that the external controller ( 250 ) may communicate or provide power to any of the implanted devices ( 140 , 140 ′, and 140 ′′) and that each of the various implanted devices ( 140 , 140 ′, and 140 ′′) may communicate with and, in some instances, control any of the other implanted devices.
  • the first and second stimulators ( 140 , 140 ′) of FIG. 4 may be configured to sense various indicators of a particular medical condition and transmit the measured information to the third stimulator ( 140 ′′).
  • the third stimulator ( 140 ′′) may then use the measured information to adjust its stimulation parameters and apply stimulation to a stimulation site accordingly (e.g., to the occipital nerves).
  • the various implanted stimulators may, in any combination, sense indicators of the medical condition, communicate or receive data on such indicators, and adjust stimulation parameters accordingly.
  • the external device ( 250 ) or other external devices communicating with the external device may be configured to sense various indicators of a patient's condition. The sensed indicators can then be collected by the external device ( 250 ) for relay to one or more of the implanted stimulators or may be transmitted directly to one or more of the implanted stimulators by any of an array of external sensing devices. In either case, the stimulator, upon receiving the sensed indicator(s), may adjust stimulation parameters accordingly. In other examples, the external controller ( 250 ) may determine whether any change to stimulation parameters is needed based on the sensed indicators. The external device ( 250 ) may then signal a command to one or more of the stimulators to adjust stimulation parameters accordingly.
  • Implanted stimulators are implanted, generally, on a long-term or permanent basis.
  • a lead from an implanted stimulator tends to move away from the location where it was first implanted.
  • a simple nod of the head may cause the position of a lead that is implanted in the neck to shift positions. This tendency is known as lead migration, or simply, migration.
  • the stimulator may continue to operate under the same stimulation parameters and output the same stimulus.
  • the position of the stimulator and/or its lead(s) has changed due to migration, the resulting stimulation experienced by the patient will be different. This may result due to a change in tissue impedance or distance or orientation of the electrodes caused by migration relative to the stimulation site. Consequently, lead migration may render the lead unable to provide the optimal treatment with minimal power consumption that was realized when the lead was more properly positioned.
  • the optimal stimulation parameters may vary depending on the particular medical condition being treated, the time of day that the stimulation is to be applied, and/or the requirements of the stimulator itself. For example, the stimulation parameters may be different during the day as opposed to during the night for a particular patient.
  • the stimulation parameters may also be configured to optimize power consumption of the stimulator. Hence, the methods and systems described herein may be used to continuously identify and select optimal stimulation parameters as best serves a particular application.
  • current steering may be used to determine the optimal stimulation parameters and compensate for lead migration.
  • Current steering is also know as neuronavigation or e-trolling.
  • current steering will be used to describe a process used to determine the optimal stimulation parameters for a particular patient.
  • FIGS. 5A-5H illustrate a number of exemplary electrode arrangements that may be a part of a stimulating lead ( 141 ; FIG. 2 ) that is used to apply a stimulus at one or more stimulation sites within a patient.
  • Each of the electrode configurations in FIGS. 5A-5H is disposed on a paddle portion ( 162 ) of the lead ( 141 ; FIG. 2 ).
  • the electrodes will also be referred to herein and in the appended claims, unless otherwise specifically denoted, as “electrode contacts” or simply “contacts.”
  • the paddle ( 162 ) may be coated with drugs that encourage such tissue growth over and around the paddle ( 162 ) to hold the paddle ( 162 ) in place.
  • the size and shape of the paddle ( 162 ) can be adjusted as best suits a particular application or implantation environment.
  • the electrode contacts ( 142 ) on the paddle ( 162 ) may be oriented on one or both side of the paddle ( 162 ) so as to direct the stimulating current to the target stimulation site. Typically, however, the contacts ( 142 ) will be arranged on one side of the paddle ( 162 ) which is then implanted in an orientation with the contacts ( 142 ) facing the tissue to be stimulated. As shown in FIGS. 5A-5H , and as will be described in more detail below, the electrode contacts ( 142 ) may be arranged in an array with a variety of configurations to facilitate different types of stimulation or provide different current steering effects.
  • the stimulator ( 140 ; FIG. 2 ) may be configured to provide monopolar and/or multipolar electrical stimulation at a stimulation site via the electrode contacts ( 142 ).
  • each electrode contact ( 142 ) may be selectively programmed or configured to act as an anode or as a cathode.
  • Each electrode contact ( 142 ) may also be programmed to be “off,” i.e., not part of the circuit deliver the stimulation current.
  • Monopolar stimulation is achieved by placing an electrode contact acting as a cathode (or anode) adjacent to or near a stimulation site, and placing an electrode of opposite polarity relatively “far away” from the stimulation site.
  • Bipolar stimulation is achieved by placing an anode-cathode pair adjacent to or near a stimulation site.
  • Tripolar stimulation is achieved by placing a cathode surrounded by two anodes or an anode surrounded by two cathodes adjacent to or near a stimulation site.
  • Monopolar and multipolar electrode configurations have different stimulation properties. For example, as illustrated in FIG. 6 , relative current threshold values vary as a function of distance from the stimulation site for each of these electrode configurations. As used herein and in the appended claims, the term “current threshold value” will be used to refer to the minimum amount of current required to stimulate, e.g., evoke a tissue response from, a stimulation site.
  • FIG. 6 is a graph illustrating the relative current threshold values of monopolar, bipolar, and tripolar electrode configurations as a function of distance from the stimulation site. The graph is based on a theoretical mathematical model of neural stimulation. The current threshold values are normalized by the current threshold of the monopolar configuration.
  • Monopolar and multipolar electrode configurations often have different stimulation localization properties. For example, a monopolar electrode configuration emits a multidirectional electrical field that may be used to stimulate a relatively general stimulation site. A multipolar electrode configuration, on the other hand, emits a more localized electrical field that is often used to stimulate a relatively specific stimulation site, and may be used to stimulate stimulation sites that have a particular orientation (e.g., a nerve).
  • a monopolar electrode configuration emits a multidirectional electrical field that may be used to stimulate a relatively general stimulation site.
  • a multipolar electrode configuration emits a more localized electrical field that is often used to stimulate a relatively specific stimulation site, and may be used to stimulate stimulation sites that have a particular orientation (e.g., a nerve).
  • the electrode contacts ( 142 ) may be made of any conducting material that will withstand and operate effectively in an implanted environment.
  • Such materials include, for example, a conducting ceramic, conducting polymer, copper, and/or a noble or refractory metal, such as gold, silver, platinum, iridium, tantalum, titanium, titanium nitride, niobium, and/or an alloy thereof.
  • a conducting ceramic, conducting polymer, copper, and/or a noble or refractory metal such as gold, silver, platinum, iridium, tantalum, titanium, titanium nitride, niobium, and/or an alloy thereof.
  • a noble or refractory metal such as gold, silver, platinum, iridium, tantalum, titanium, titanium nitride, niobium, and/or an alloy thereof.
  • the use of one or more of these materials in constructing the electrode contacts ( 142 ) may serve to minimize corrosion, electrolysis, and/or damage to surrounding tissues.
  • the surfaces of the electrode contacts ( 142 ) may have any of a number of properties.
  • the surfaces may be smooth or rough.
  • a rough surface increases the actual surface area of an electrode contact and may, with some materials (e.g., platinum or iridium), increase the pseudo-capacitance of the electrode contact.
  • An increased pseudo-capacitance may serve to minimize the risk of adverse electrical affects to a patient being treated.
  • a rough surface may also serve to minimize lead migration.
  • the electrode contacts ( 142 ) may have any suitable size or shape. Differently shaped electrode contacts ( 142 ) provide different current densities. For example, a round or oval electrode contact, as shown in FIGS. 5A-5H , may provide a more uniform current density than an electrode contact that is rectangular. However, the shape of the electrode contacts ( 142 ) may vary as best serves a particular application.
  • FIGS. 5A-5H illustrate a number of exemplary electrode contact arrangements that may be used to provide monopolar and/or multipolar stimulation at a stimulation site.
  • the electrode contact arrangements shown in FIGS. 5A-5H are merely illustrative of the many different electrode contact arrangements that may be used to provide monopolar and/or multipolar stimulation at a stimulation site.
  • FIG. 5A shows a first electrode contact arrangement that may be used to provide monopolar and/or multipolar stimulation at a stimulation site.
  • the electrode contact arrangement of FIG. 5A includes a center electrode contact ( 142 - 1 ) surrounded by three electrode contacts ( 142 - 2 , 3 , 4 ) in an equilateral triangle or trigonal planar configuration.
  • each of the electrode contacts ( 142 ) may be selectively configured to act as an anode or cathode.
  • monopolar stimulation may be achieved by using, for example, the top electrode contact ( 142 - 2 ) and one of the bottom electrode contacts (e.g., 142 - 3 ) as an anode-cathode pair.
  • Bipolar stimulation may be achieved by using, for example, the center electrode contact ( 142 - 1 ) with one of the other electrode contacts (e.g., 142 - 2 ) as an anode-cathode pair.
  • Tripolar stimulation may be achieved by using, for example, the center electrode contacts ( 142 - 1 ) with two of the other electrode contacts (e.g., 142 - 3 and 142 - 4 ) in an anode-cathode-anode or cathode-anode-cathode configuration.
  • FIGS. 5A-5H there are many possible configurations for the electrode contact array.
  • the illustrated examples are merely exemplary and other configurations are within the scope of the principles described herein.
  • FIG. 5B illustrates a configuration with a central electrode contact ( 142 ) and four additional electrode contacts ( 142 ) arranged in a square around the central electrode contact ( 142 ).
  • the four additional electrode contacts ( 142 ) may be located at the corners of a square paddle lead as shown in FIG. 5B .
  • FIG. 5C illustrated a line of four electrode contacts ( 142 ) with a line of two electrode contacts ( 142 ) both above and below the line of four, with the lines of two electrode contacts ( 142 ) each being centered with respect to the larger line of four.
  • FIG. 5D illustrates a similar configuration only with two lines of four electrode contacts ( 142 ) arranged between the upper and lower lines of two.
  • FIG. 5E illustrates a configuration in which the electrode contacts ( 142 ) are arranged in a two-by-four rectangular array.
  • FIG. 5F illustrates a configuration in which a line of four electrodes is disposed adjacent a line of three electrodes, both lines being centered with respect to a rectangular paddle.
  • FIG. 5G illustrated a configuration with six electrode contacts ( 142 ) in three columns of two electrode contacts ( 142 ) each. The center column is offset vertically with respect to the two side columns.
  • FIG. 5H illustrates a configuration in which the electrode contacts ( 142 ) are arranged in a circle or ring pattern. Each configuration illustrated and other possible configurations for the electrode contacts ( 142 ) will provide different current steering options and may be particularly well suited to treating a particular condition or patient.
  • FIG. 7 is a flow chart illustrating an exemplary method of current steering that may be used to determine the optimal stimulation parameters for a particular patient.
  • the steps shown in FIG. 7 are merely illustrative and may be modified, reordered, or removed as best serves a particular application.
  • the steps shown in FIG. 7 may be performed by a processor or the like via a set of computer readable instructions.
  • These computer readable instructions may be constructed in any programming language, such as Java or C, for example, and stored on any medium configured to store computer readable instructions such as a flash drive, memory chip, compact disk (CD), digital versatile disc (DVD), floppy disk, or hard drive, for example.
  • one or more of the electrode contacts ( 142 ; FIGS. 5A-5H ) are programmed to act as anodes (step 700 ).
  • One or more of the electrode contacts ( 142 ; FIGS. 5A-5H ) are also programmed to act as cathodes (step 701 ). It is also possible that one or more of the electrode contacts are programmed to be “off.”
  • any of the other stimulation parameters may also be adjusted (step 702 ).
  • the frequency, pulse width, amplitude, burst pattern e.g., burst on time and burst off time
  • duty cycle or burst repeat interval e.g., ramp on time, and/or ramp off time of the stimulation current applied by each of the electrode contacts ( 142 ; FIGS. 5A-5H ) may be adjusted.
  • a stimulation current is generated by the stimulator ( 140 ; FIG. 2 ) and applied via the electrode contacts ( 142 ; FIGS. 5A-5H ) (step 703 ).
  • the process is repeated until it is determined that the stimulation is optimal (Yes; step 704 ). Exemplary methods for determining when the stimulation is optimized will be described below. In some examples, the process is repeated until all possible combinations of anode and cathode assignments are tested.
  • a number of techniques may be used to determine whether the stimulation applied by the electrode contacts ( 142 ; FIGS. 5A-5H ) is optimal (step 704 ).
  • patient feedback may be used to determine the optimal stimulation parameters. For example, if the stimulation is being applied to a nerve (e.g., the greater or lesser occipital nerves) to treat chronic headache pain, the stimulation parameters may be adjusted until the patient indicates that the greatest amount of relief from the headache pain has been achieved.
  • a neural response to a particular set of stimulation parameters may be measured by a recording electrode or other device. The stimulation parameters may be adjusted until an optimal neural response is measured. Any other method may be used as best serves a particular application to determine the optimal stimulation parameters.
  • the current steering method described in connection with FIG. 7 may be performed automatically with a computerized programming station or another suitable programming device.
  • the programming device may include a self-contained hardware/software system, or it may include software running on a standard personal computer (PC).
  • Exemplary programming devices include, but are not limited to, the clinician programming system ( 157 ; FIG. 2 ) and the hand held programmer ( 155 ; FIG. 2 ) described above.
  • the programming device may include a transmitting coil attachment configured to communicate with the implanted stimulator ( 140 ; FIG. 2 ). Alternatively, the programming device may be included within the stimulator ( 140 ; FIG. 2 ) itself.
  • the current steering method may be performed manually.
  • a physician or patient may manually steer the current with the aid of a computer, hand-held programmer, joystick, or other device.
  • FIGS. 8A-8C include the exemplary electrode arrangement of FIG. 5A .
  • the current may be steered in a clockwise path to find the best cathode-anode combination for a particular patient.
  • FIGS. 8A-8C include the exemplary electrode arrangement of FIG. 5A .
  • the current may be steered in a clockwise path to find the best cathode-anode combination for a particular patient.
  • the center electrode contact ( 142 - 1 ) is initially programmed as an anode (+) and the top electrode contact ( 142 - 2 ) is initially programmed as a cathode ( ⁇ ).
  • the bottom electrode contacts ( 142 - 3 , 4 ) are programmed to be off.
  • the stimulation current flows from the center electrode contact ( 142 - 1 ) to the top electrode contact ( 142 - 2 ) and creates an electric field E 1 , as shown in FIG. 8A .
  • the top electrode contact ( 142 - 2 ) is then turned off and the bottom right electrode contact ( 142 - 4 ) is programmed to act as a cathode ( ⁇ ), as shown in FIG. 8B .
  • the current now flows from the center electrode contact ( 142 - 1 ) to the bottom right electrode contact ( 142 - 4 ), as indicated by the arrow labeled E 2 .
  • the bottom right electrode contact ( 142 - 4 ) is then turned off and the bottom left electrode contact ( 142 - 3 ) is programmed to act as a cathode ( ⁇ ), as shown in FIG. 8C .
  • the resulting current flow, E 3 is now between the center electrode contact ( 142 - 1 ) and the bottom left electrode contact ( 142 - 3 ).
  • This process may be repeated with some or all of the other combinations of anodes and cathodes until the optimal cathode-anode configuration is found.
  • the current may be steered in any path as best serves a particular application and that other stimulation parameters (e.g., frequency, pulse width, amplitude, burst pattern (e.g., burst on time and burst off time), duty cycle or burst repeat interval, ramp on time, and/or ramp off time) may additionally or alternatively be adjusted to determine the optimal stimulation parameters for a particular application.
  • the current steering methods and systems described herein are used when the lead ( 141 ; FIG. 2 ) and stimulator ( 140 ; FIG. 2 ) are initially implanted within the patient to determine the initial stimulation parameters that are best suited for the particular patient. Additionally or alternatively, the current steering methods and systems described herein may be used subsequently to account for lead migration and other changes within the patient that may occur after implantation.
  • the methods and systems described herein are particularly useful in stimulating nerves within the head or neck to treat headache pain and/or other medical conditions. However, it will be recognized that the methods and systems described herein may be used to stimulate any stimulation site within the patient to treat any medical condition.
  • the stimulator may be configured to additionally or alternatively infuse one or more drugs at the stimulation site.
  • the one or more drugs may have charges that are attracted to or repelled by the electrode contacts acting as anodes and cathodes.
  • a drug having a positive charge may be attracted to a cathode having a negative charge and repelled by an anode having a positive charge.
  • a drug may be steered to a particular stimulation site by appropriately programming the electrode contacts to have positive or negative charges.

Abstract

Systems for treating a patient with a medical condition include a lead having an array of electrode contacts each being programmable to have either a first polarity or a second polarity and a programming device configured to test a multiplicity of different electrode contact polarity configurations in which a programmed polarity of one or more of the electrode contacts is varied. Methods of using an implantable stimulator system include implanting a lead having an array of programmable electrode contacts disposed thereon in communication with a stimulation site, testing a multiplicity of different electrode contact polarity configurations in which a programmed polarity of one or more of the electrode contacts is varied, selecting an optimal electrode contact polarity configuration out of the multiplicity of different electrode contact polarity configurations, and applying the stimulation current via the optimal electrode contact polarity configuration to the stimulation site in accordance with one or more stimulation parameters.

Description

    RELATED APPLICATIONS
  • The present application claims the priority under 35 U.S.C. § 119 (e) of previous U.S. Provisional Patent Application No. 60/661,700, filed Mar. 14, 2005 for “Headache Treatment.” This provisional application is hereby incorporated by reference in its entirety.
  • BACKGROUND
  • A wide variety of medical conditions and disorders have been successfully treated using an implantable stimulator. Implantable stimulators typically stimulate internal tissue, such as a nerve, by emitting an electrical stimulation current according to programmed stimulation parameters.
  • One type of implantable stimulator is known as a microstimulator. Microstimulators are typically formed with a small, cylindrical housing containing electronic circuitry that produces the desired electric stimulation current between spaced electrodes. These stimulators are implanted proximate to the target tissue so that the stimulation current produced by the electrodes stimulates the target tissue to reduce symptoms or otherwise provide therapy for a wide variety of conditions and disorders. Exemplary microstimulators are described in U.S. Pat. Nos. 5,312,439; 5,193,539; 5,193,540; and 5,405,367; 6,185,452; and 6,214,032. All of these listed patents are incorporated by reference in their respective entireties.
  • Another type of implantable stimulator is known as an implantable pulse generator (IPG). A typical IPG includes a multi-channel pulse generator housed in a rounded titanium case. The IPG is generally coupled to a lead with a number of electrodes disposed thereon. Stimulation current is generated by the IPG and delivered to target tissue via the electrodes on the lead. Exemplary IPGs are described in U.S. Pat. Nos. 6,381,496; 6,553,263; and 6,760,626. All of these listed patents are incorporated by reference in their respective entireties.
  • As will be readily appreciated, a key part of patient treatment using an implanted stimulator is the proper placement of the stimulator such that the stimulation electrodes are proximate to the stimulation site to be stimulated. If the stimulation electrodes are optimally placed near the stimulation site, stimulation can be affected over a wide range of parameters and power consumption can be minimized. However, optimal placement of a stimulator within a patient is often difficult to accomplish.
  • SUMMARY
  • Systems for treating a patient with a medical condition include a lead having an array of electrode contacts each being programmable to have either a first polarity or a second polarity and a programming device configured to test a multiplicity of different electrode contact polarity configurations in which a programmed polarity of one or more of the electrode contacts is varied.
  • Methods of using an implantable stimulator system include implanting a lead having an array of programmable electrode contacts disposed thereon in communication with a stimulation site, testing a multiplicity of different electrode contact polarity configurations in which a programmed polarity of one or more of the electrode contacts is varied, selecting an optimal electrode contact polarity configuration out of the multiplicity of different electrode contact polarity configurations, and applying the stimulation current via the optimal electrode contact polarity configuration to the stimulation site in accordance with one or more stimulation parameters.
  • BRIEF DESCRIPTION OF THE DRAWINGS
  • The accompanying drawings illustrate various embodiments of the present invention and are a part of the specification. The illustrated embodiments are merely examples of the present invention and do not limit the scope of the invention.
  • FIG. 1A depicts the upper cervical spine area of a patient and shows a number of nerves originating in the upper cervical spine area.
  • FIG. 1B shows various nerves in the back of the head and neck.
  • FIG. 1C illustrates a view of the major nerves and arteries in the human head as viewed from above looking down on the top or superior part of the head.
  • FIGS. 1D and 1E depict the trigeminal nerve and its branches.
  • FIG. 2 illustrates an exemplary stimulator that may be used to apply a stimulus to a target nerve to treat a particular medical condition according to principles described herein.
  • FIG. 3 illustrates an exemplary microstimulator that may be used as the stimulator according to principles described herein.
  • FIG. 4 depicts a number of stimulators configured to communicate with each other and/or with one or more external devices according to principles described herein.
  • FIGS. 5A-5H illustrate a number of exemplary electrode contact arrangements that may be a part of a stimulating lead that is used to apply a stimulation at one or more stimulation sites within a patient according to principles described herein.
  • FIG. 6 is a graph illustrating the relative current threshold values of monopolar, bipolar, and tripolar electrode configurations as a function of distance from the stimulation site according to principles described herein.
  • FIG. 7 is a flow chart illustrating an exemplary method of current steering that may be used to determine the optimal stimulation parameters for a patient according to principles described herein.
  • FIGS. 8A-8C illustrate an exemplary method of current steering according to principles described herein.
  • Throughout the drawings, identical reference numbers designate similar, but not necessarily identical, elements.
  • DETAILED DESCRIPTION
  • Systems and methods for treating a patient with a medical condition are described herein. A lead with an array of electrode contacts is implanted in communication with a stimulation site. The lead is coupled at a proximal end to an implantable stimulator that is configured to generate a stimulus, such as an electrical stimulation current. Each of the electrode contacts of the array may be selectively programmed to function as an anode or cathode. Thus, many different electrode contact polarity configurations can be realized depending on which electrodes function as anodes and which as cathodes. Current steering methods are then used to test a multiplicity of different electrode contact polarity configurations and select an optimal electrode contact polarity configuration for applying the stimulus to a stimulation site within the patient.
  • In the following description, for purposes of explanation, numerous specific details are set forth in order to provide a thorough understanding of the present systems and methods. It will be apparent, however, to one skilled in the art that the present systems and methods may be practiced without these specific details. Reference in the specification to “one embodiment” or “an embodiment” means that a particular feature, structure, or characteristic described in connection with the embodiment is included in at least one embodiment. The appearance of the phrase “in one embodiment” in various places in the specification are not necessarily all referring to the same embodiment.
  • FIG. 1A depicts the upper cervical spine area (C1-C4) of a patient. As shown in FIG. 1A, a number of nerves arise from the upper cervical spine area (C1-C4). Examples of such nerves include, but are not limited to, the greater occipital nerve(s)
  • (132), lesser occipital nerve(s) (134), greater auricular nerve(s) (136), transverse cervical nerve(s) (138), supraclavicular nerve(s) (139), and/or branches of any of these nerves.
  • FIG. 1B depicts the occipital nerves (130) in the back or posterior portion of the head and upper neck area of a patient. As shown in FIG. 1B, the occipital nerves (130) are divided into greater (132) and lesser (134) occipital nerves. The occipital nerves (130) lie subcutaneously in the posterior of the head and upper neck and are therefore relatively easily accessed. Thus, as will be described in more detail below, a stimulator and/or electrode lead may be implanted in the posterior of the head or in the upper neck area of a patient to provide a stimulus to the occipital nerves (130).
  • FIG. 1C illustrates a view of the major nerves and arteries in the human head as viewed from above looking down on the top or superior part of the head. As shown in FIG. 1C, the greater occipital nerves (132) extend to and across some of the top or superior portion of the head. The lesser occipital nerves (134) may also extend to or near the top or superior portion of the head. Consequently, an implanted stimulator or an electrode lead may be positioned along the posterior part of the head or on the superior portion of the head and still provide a stimulus to the occipital nerves (130).
  • FIGS. 1D and 1E depict the trigeminal nerve (100) and its branches. The trigeminal nerve (100) and its branches are responsible, in part, for the perception of head pain, including headaches and facial pain. The trigeminal nerve (100) on each side of the head arises from a trigeminal ganglion (102), which lies within the skull in an area known as Meckel's cave (110). Access to either trigeminal ganglion (102) may be achieved via the foramen ovale (112) or the foramen rotundum (114).
  • Procedures that ablate the trigeminal ganglia (102) do not disable the muscles of mastication, since the cell bodies of the sensory portion of the nerve are within the trigeminal ganglia (102), whereas the motor portion simply projects axons through the ganglia (the motor neuron cell bodies are in the pons). This may provide a mechanism for selective stimulation of the sensory cells via appropriate placement of a stimulator for stimulation of one or both trigeminal ganglia (102).
  • FIGS. 1D and 1E also show a number of braches of the trigeminal nerve (100) including, but not limited to, the ophthalmic nerve (120), the maxillary nerve (122), and the mandibular nerve (124). The supraorbital nerve (not shown) is also a branch of the trigeminal nerve (100). The ophthalmic nerve (120) and the maxillary nerve (122) are entirely sensory, and sufficiently separate to allow independent and selective stimulation via appropriate placement of a stimulator.
  • The mandibular nerve (124) is both sensory and motor. The mandibular nerve (124) innervates several facial muscles, including the muscles of mastication and the tensor tympani, which reflexively damps down the vibrations of the malleus by increasing the tension in the tympanic membrane. However, just distal to the foramen ovale (112), the mandibular nerve (124) splits into a purely sensory branch that innervates the superior part of the lower jaw. And, slightly more distally, another branch splits into a purely sensory branch that innervates the inferior part of the lower jaw. These branches may be sufficiently separate to allow independent and selective stimulation via appropriate placement of a stimulator.
  • It has been discovered that stimulating one or more of the nerves in the head with an electrical stimulation current can alleviate or eliminate headache pain. This is especially useful for patients who do not respond to other forms of treatment or who do not prefer any of the other forms of treatment. Consequently, a stimulator may be implanted in a patient to deliver an electrical stimulation current to one or more of the nerves in the head, particularly the occipital nerves (130). This stimulation may be effective to treat headache pain (including, but not limited to chronic migraine headaches) and other types of pain or medical conditions, such as occipital neuralgia, facial pain, Bells palsy, etc. It will be recognized that the stimulator may additionally or alternatively be implanted in any site within the body and configured to treat any other medical condition such as, but not limited to, incontinence, peripheral nerve damage, sexual dysfunction, etc.
  • As used herein, and in the appended claims, the term “stimulator” will be used broadly to refer any device that delivers a stimulus, such as an electrical stimulation current, one or more drugs or other chemical stimulation, thermal stimulation, electromagnetic stimulation, mechanical stimulation, and/or any other suitable stimulation at a stimulation site. Thus, the term “stimulator” includes, but is not limited to, a stimulator, microstimulator, implantable pulse generator (IPG), system control unit (stimulator) or similar device.
  • The stimulation site referred to herein may include any nerve, tissue, blood vessel, or other area within the patient. For example, the stimulation site may include one or more of the following nerves: any cranial nerve; the greater, lesser or third occipital nerves; the trigeminal nerve; the infraorbital nerve; the facial nerve; the maxillary nerve, the mandibular nerve and divisions of those nerves such as the two branches of the ophthalmic division of the trigeminal nerve, i.e., the supratrochlear and supraorbital nerves; the zygomaticotemporal nerve branching from the maxillary division of the trigeminal nerve; the auriculotemporal nerve branching from the mandibular division of the trigeminal nerve; the pudendal nerve; and the cavernous nerve. The stimulation site may additionally or alternatively include the cortex, spinal cord, or any other area of the central nervous system. In some examples, the stimulation site may include two or more stimulation sites, e.g., the occipital and trigeminal nerves.
  • To facilitate an understanding of the methods of optimally placing a stimulator within a patient to treat a medical condition, a more detailed description of the stimulator and its operation will now be given with reference to the figures. FIG. 2 illustrates an exemplary stimulator (140) that may be implanted within a patient (150) and used to apply a stimulus to a stimulation site, e.g., an electrical stimulation of the stimulation site, an infusion of one or more drugs at the stimulation site, or both. The electrical stimulation function of the stimulator (140) will be described first, followed by an explanation of the possible drug delivery function of the stimulator (140). It will be understood, however, that the stimulator (140) may be configured to provide only electrical stimulation, only a drug stimulation, both types of stimulation or any other type of stimulation as best suits a particular patient.
  • The exemplary stimulator (140) shown in FIG. 2 is configured to provide electrical stimulation at a stimulation site within a patient and includes a lead (141) having a proximal end coupled to the body of the stimulator (140). In some examples, as will be described in more detail below, a distal end of the lead (141) may be formed as a flat enlarged surface (162), referred to herein as a paddle, and implanted such that it is in communication with a stimulation site. As used herein and in the appended claims, the term “in communication with” refers to the lead (141) or other device being adjacent, in the general vicinity, in close proximity, directly next to, or directly on the stimulation site such that a desired stimulation can be effectively delivered.
  • A number of electrodes (142) may be disposed on the paddle (162), as illustrated in FIG. 2. The electrodes (142) may be arranged on the paddle (162) in a variety of different possible configurations. As will be described in more detail below, the electrodes (142) are configured to apply an electrical stimulation current to the stimulation site as best suits a particular application.
  • As illustrated in FIG. 2, the stimulator (140) includes a number of components. It will be recognized that the stimulator (140) may include additional and/or alternative components as best serves a particular application. A power source (145) is configured to output voltage used to supply the various components within the stimulator (140) with power and/or to generate the power used for electrical stimulation. The power source (145) may be a primary battery, a rechargeable battery, super capacitor, a nuclear battery, a mechanical resonator, an infrared collector (receiving, e.g., infrared energy through the skin), a thermally-powered energy source (where, e.g., memory-shaped alloys exposed to a minimal temperature difference generate power), a flexural powered energy source (where a flexible section subject to flexural forces is part of the stimulator), a bioenergy power source (where a chemical reaction provides an energy source), a fuel cell, a bioelectrical cell (where two or more electrodes use tissue-generated potentials and currents to capture energy and convert it to useable power), an osmotic pressure pump (where mechanical energy is generated due to fluid ingress), or the like. Alternatively, the stimulator (140) may include one or more components configured to receive power from another medical device that is implanted within the patient.
  • When the power source (145) is a battery, it may be a lithium-ion battery or other suitable type of battery. When the power source (145) is a rechargeable battery, it may be recharged from an external system through a power link such as a radio frequency (RF) power link. One type of rechargeable battery that may be used is described in International Publication WO 01/82398 A1, published Nov. 1, 2001, and/or WO 03/005465 A1, published Jan. 16, 2003, both of which are incorporated herein by reference in their respective entireties. Other battery construction techniques that may be used to make a power source (145) include those shown, e.g., in U.S. Pat. Nos. 6,280,873; 6,458,171, and U.S. Publications 2001/0046625 A1 and 2001/0053476 A1, all of which are incorporated herein by reference in their respective entireties. Recharging can be performed using an external charger.
  • The stimulator (140) may also include a coil (148) configured to receive and/or emit a magnetic field (also referred to as a radio frequency (RF) field) that is used to communicate with, or receive power from, one or more external devices (151, 153, 155). Such communication and/or power transfer may include, but is not limited to, transcutaneously receiving data from the external device, transmitting data to the external device, and/or receiving power used to recharge the power source (145).
  • For example, an external battery charging system (EBCS) (151) may provide power used to recharge the power source (145) via an RF link (152). External devices including, but not limited to, a hand held programmer (HHP) (155), clinician programming system (CPS) (157), and/or a manufacturing and diagnostic system (MDS)
  • (153) may be configured to activate, deactivate, program, and test the stimulator (140) via one or more RF links (154, 156). It will be recognized that the links, which are RF links (152, 154, 156) in the illustrated example, may be any type of link used to transmit data or energy, such as an optical link, a thermal link, or any other energy-coupling link. One or more of these external devices (153, 155, 157) may also be used to control the infusion of one or more drugs into the stimulation site.
  • Additionally, if multiple external devices are used in the treatment of a patient, there may be some communication among those external devices, as well as with the implanted stimulator (140). Again, any type of link for transmitting data or energy may be used among the various devices illustrated. For example, the CPS (157) may communicate with the HHP (155) via an infrared (IR) link (158), with the MDS (153) via an IR link (161), and/or directly with the stimulator (140) via an RF link (160). As indicated, these communication links (158, 161, 160) are not necessarily limited to IR and RF links and may include any other type of communication link. Likewise, the MDS (153) may communicate with the HHP (155) via an IR link (159) or via any other suitable communication link.
  • The HHP (155), MDS (153), CPS (157), and EBCS (151) are merely illustrative of the many different external devices that may be used in connection with the stimulator (140). Furthermore, it will be recognized that the functions performed by any two or more of the HHP (155), MDS (153), CPS (157), and EBCS (151) may be performed by a single external device. One or more of the external devices (153, 155, 157) may be embedded in a seat cushion, mattress cover, pillow, garment, belt, strap, pouch, or the like so as to be positioned near the implanted stimulator (140) when in use.
  • The stimulator (140) may also include electrical circuitry (144) configured to produce electrical stimulation pulses that are delivered to the stimulation site via the electrodes (142). In some embodiments, as will be described in more detail below, the stimulator (140) may be configured to produce monopolar stimulation. The stimulator (140) may alternatively or additionally be configured to produce multipolar stimulation including, but not limited to, bipolar or tripolar stimulation.
  • The electrical circuitry (144) may include one or more processors configured to decode stimulation parameters and generate the stimulation pulses. In some embodiments, the stimulator (140) has at least four channels and drives up to sixteen electrodes or more. The electrical circuitry (144) may include additional circuitry such as capacitors, integrated circuits, resistors, coils, and the like configured to perform a variety of functions as best serves a particular application.
  • The stimulator (140) may also include a programmable memory unit (146) for storing one or more sets of data and/or stimulation parameters. The stimulation parameters may include, but are not limited to, electrical stimulation parameters, drug stimulation parameters, and other types of stimulation parameters. The programmable memory (146) allows a patient, clinician, or other user of the stimulator (140) to adjust the stimulation parameters such that the stimulation applied by the stimulator (140) is safe and efficacious for treatment of a particular patient. The different types of stimulation parameters (e.g., electrical stimulation parameters and drug stimulation parameters) may be controlled independently. However, in some instances, the different types of stimulation parameters are coupled. For example, electrical stimulation may be programmed to occur only during drug stimulation or vice versa. Alternatively, the different types of stimulation may be applied at different times or with only some overlap. The programmable memory (146) may be any type of memory unit such as, but not limited to, random access memory (RAM), static RAM (SRAM), a hard drive, or the like.
  • The electrical stimulation parameters may control various parameters of the stimulation current applied to a stimulation site including, but not limited to, the frequency, pulse width, amplitude, electrode configuration (i.e., anode-cathode assignment), burst pattern (e.g., burst on time and burst off time), duty cycle or burst repeat interval, ramp on time, and ramp off time of the stimulation current that is applied to the stimulation site. The drug stimulation parameters may control various parameters including, but not limited to, the amount of drugs infused at the stimulation site, the rate of drug infusion, and the frequency of drug infusion. For example, the drug stimulation parameters may cause the drug infusion rate to be intermittent, constant, or bolus. Other stimulation parameters that characterize other classes of stimuli are possible. For example, when tissue is stimulated using electromagnetic radiation, the stimulation parameters may characterize the intensity, wavelength, and timing of the electromagnetic radiation stimuli. When tissue is stimulated using mechanical stimuli, the stimulation parameters may characterize the pressure, displacement, frequency, and timing of the mechanical stimuli.
  • Specific stimulation parameters may have different effects on different types of medical conditions. Thus, in some embodiments, the stimulation parameters may be adjusted by the patient, a clinician, or other user of the stimulator (140) as best serves a particular medical condition. The stimulation parameters may also be automatically adjusted by the stimulator (140), as will be described below. For example, the amplitude of the stimulus current applied to a stimulation site may be adjusted to have a relatively low value so as to target relatively large diameter fibers of the stimulation site. The stimulator (140) may also, or alternatively, increase excitement of a stimulation site by applying a stimulation current having a relatively low frequency (e.g., less than 100 Hz) to the stimulation site. The stimulator (140) may also decrease excitement of a stimulation site by applying a relatively high frequency (e.g., greater than 100 Hz) to the stimulation site. The stimulator (140) may also, or alternatively, be programmed to apply the stimulation current to a stimulation site intermittently or continuously.
  • Additionally, the exemplary stimulator (140) shown in FIG. 2 is configured to provide drug stimulation to a patient, for example, a headache patient, by applying one or more drugs to a stimulation site. For this purpose, a pump (147) may also be included within the stimulator (140). The pump (147) is configured to store and dispense one or more drugs, for example, through a catheter (143). The catheter (143) is coupled at a proximal end to the stimulator (140) and may have an infusion outlet (149) for infusing dosages of the one or more drugs at the stimulation site. In some embodiments, the stimulator (140) may include multiple catheters (143) and/or pumps (147) for storing and infusing dosages of the one or more drugs at the stimulation site.
  • The pump (147) or controlled drug release device described herein may include any of a variety of different drug delivery systems. Controlled drug release devices based upon a mechanical or electromechanical infusion pump may be used. In other examples, the controlled drug release device can include a diffusion-based delivery system, e.g., erosion-based delivery systems (e.g., polymer-impregnated with drug placed within a drug-impermeable reservoir in communication with the drug delivery conduit of a catheter), electrodiffusion systems, and the like. Another example is a convective drug delivery system, e.g., systems based upon electroosmosis, vapor pressure pumps, electrolytic pumps, effervescent pumps, piezoelectric pumps and osmotic pumps. Another example is a micro-drug pump.
  • Exemplary pumps (147) or controlled drug release devices suitable for use as described herein include, but are not necessarily limited to, those disclosed in U.S. Pat. Nos. 3,760,984; 3,845,770; 3,916,899; 3,923,426; 3,987,790; 3,995,631; 3,916,899; 4,016,880; 4,036,228; 4,111,202; 4,111,203; 4,203,440; 4,203,442; 4,210,139; 4,327,725; 4,360,019; 4,487,603; 4,627,850; 4,692,147; 4,725,852; 4,865,845; 5,057,318; 5,059,423; 5,112,614; 5,137,727; 5,234,692; 5,234,693; 5,728,396; 6,368,315 and the like. Additional exemplary drug pumps suitable for use as described herein include, but are not necessarily limited to, those disclosed in U.S. Pat. Nos. 4,562,751; 4,678,408; 4,685,903; 5,080,653; 5,097,122; 6,740,072; and 6,770,067. Exemplary micro-drug pumps suitable for use as described herein include, but are not necessarily limited to, those disclosed in U.S. Pat. Nos. 5,234,692; 5,234,693; 5,728,396; 6,368,315; 6,666,845; and 6,620,151. All of these listed patents are incorporated herein by reference in their respective entireties.
  • The stimulator (140) of FIG. 2 is illustrative of many types of stimulators that may be used to apply a stimulus to a stimulation site to treat headaches and other medical conditions. For example, the stimulator (140) may include an implantable pulse generator (EPG) coupled to one or more leads having a number of electrodes, a spinal cord stimulator (SCS), a cochlear implant, a deep brain stimulator, a drug pump (mentioned previously), a micro-drug pump (mentioned previously), or any other type of implantable stimulator configured to deliver a stimulus at a stimulation site within a patient. Exemplary IPGs suitable for use as described herein include, but are not limited to, those disclosed in U.S. Pat. Nos. 6,381,496; 6,553,263; and 6,760,626. Exemplary spinal cord stimulators suitable for use as described herein include, but are not limited to, those disclosed in U.S. Pat. Nos. 5,501,703; 6,487,446; and 6,516,227. Exemplary cochlear implants suitable for use as described herein include, but are not limited to, those disclosed in U.S. Pat. Nos. 6,219,580; 6,272,382; and 6,308,101. Exemplary deep brain stimulators suitable for use as described herein include, but are not limited to, those disclosed in U.S. Pat. Nos. 5,938,688; 6,016,449; and 6,539,263. All of these listed patents are incorporated herein by reference in their respective entireties.
  • Alternatively, the stimulator (140) may include an implantable microstimulator, such as a BION® microstimulator (Advanced Bionics® Corporation, Valencia, Calif.). Various details associated with the manufacture, operation, and use of implantable microstimulators are disclosed in U.S. Pat. Nos. 5,193,539; 5,193,540; 5,312,439; 6,185,452; 6,164,284; 6,208,894; and 6,051,017. All of these listed patents are incorporated herein by reference in their respective entireties.
  • FIG. 3 illustrates an exemplary microstimulator (200) that may be used as the stimulator (140; FIG. 2) described herein. Other configurations of the microstimulator (200) are possible, as shown in the above-referenced patents and as described further below.
  • As shown in FIG. 3, the microstimulator (200) may include the power source (145), the programmable memory (146), the electrical circuitry (144), and the pump (147) described in connection with FIG. 2. These components are housed within a capsule (202). The capsule (202) may be a thin, elongated cylinder or any other shape as best serves a particular application. The shape of the capsule (202) may be determined by the structure of the desired target nerve, the surrounding area, and the method of implantation. In some embodiments, the volume of the capsule (202) is substantially equal to or less than three cubic centimeters. In some embodiments, the microstimulator (200) may include two or more leadless electrodes (142) disposed on the outer surface of the microstimulator (200).
  • The external surfaces of the microstimulator (200) may advantageously be composed of biocompatible materials. For example, the capsule (202) may be made of glass, ceramic, metal, or any other material that provides a hermetic package that will exclude water vapor but permit passage of electromagnetic fields used to transmit data and/or power. The electrodes (142) may be made of a noble or refractory metal or compound, such as platinum, iridium, tantalum, titanium, titanium nitride, niobium or alloys of any of these, in order to avoid corrosion or electrolysis which could damage the surrounding tissues and the device.
  • The microstimulator (200) may also include one or more infusion outlets (201). The infusion outlets (201) facilitate the infusion of one or more drugs at a treatment site to treat a particular medical condition. The infusion outlets (201) may dispense one or more drugs directly to the treatment site. Alternatively, catheters may be coupled to the infusion outlets (201) to deliver the drug therapy to a treatment site some distance from the body of the microstimulator (200). The stimulator (200) of FIG. 3 also includes electrodes (142-1 and 142-2) at either end of the capsule (202). One of the electrodes (142) may be designated as a stimulating electrode to be placed close to the treatment site and one of the electrodes (142) may be designated as an indifferent electrode used to complete a stimulation circuit.
  • The microstimulator (200) may be implanted within a patient with a surgical tool such as a hypodermic needle, bore needle, or any other tool specially designed for the purpose. Alternatively, the microstimulator (200) may be implanted using endoscopic or laparoscopic techniques.
  • A stimulator may be configured to operate independently. Alternatively, as shown in FIG. 4 and described in more detail below, the stimulator (140) may be configured to operate in a coordinated manner with one or more additional stimulators, other implanted devices, or other devices external to the patient's body. For instance, a first stimulator may control, or operate under the control of, a second stimulator, other implanted device, or other device external to the patient's body. The stimulator (140) may be configured to communicate with other implanted stimulators, other implanted devices, or other devices external to the patient's body via an RF link, an untrasonic link, an optical link, or any other type of communication link. For example, the stimulator (140) may be configured to communicate with an external remote control unit that is capable of sending commands and/or data to the stimulator (140) and that is configured to receive commands and/or data from the stimulator (140).
  • In order to determine the strength and/or duration of electrical stimulation and/or amount and/or type(s) of stimulating drug(s) required to most effectively treat a medical condition, various indicators of the medical condition and/or a patient's response to treatment may be sensed or measured. These indicators include, but are not limited to, electrical activity of the brain (e.g., EEG); neurotransmitter levels; hormone levels; metabolic activity in the brain; blood flow rate in the head, neck or other areas of the body; medication levels within the patient; patient input, e.g. when prodromal symptoms are sensed the patient can push a button on a remote control or other external unit; temperature of tissue in the stimulation target region, including the occipital nerve; physical activity level, e.g. based on accelerometer recordings; brain hyperexcitability, e.g. increased response of given tissue to the same input; indicators of collateral tissue stimulation might be used to adjust stimulation parameters; and/or detection of muscle tone in neck (mechanical strain, pressure sensor, EMG). In some embodiments, the stimulator (140) may be configured to change the stimulation parameters in a closed loop manner in response to these measurements. The stimulator (140) may be configured to perform the measurements. Alternatively, other sensing devices may be configured to perform the measurements and transmit the measured values to the stimulator (140). Exemplary sensing devices include, but are not limited to, chemical sensors, electrodes, optical sensors, mechanical (e.g., motion, pressure) sensors, and temperature sensors.
  • Thus, one or more external devices may be provided to interact with the stimulator (140), and may be used to accomplish at least one or more of the following functions:
  • Function 1: If necessary, transmit electrical power to the stimulator (140) in order to power the stimulator (140) and/or recharge the power source (145).
  • Function 2: Transmit data to the stimulator (140) in order to change the stimulation parameters used by the stimulator (140).
  • Function 3: Receive data indicating the state of the stimulator (140) (e.g., battery level, drug level, stimulation parameters, etc.).
  • Additional functions may include adjusting the stimulation parameters based on information sensed by the stimulator (140) or by other sensing devices.
  • By way of example, an exemplary method of treating a patient with a medical condition may be carried out according to the following sequence of procedures. The steps listed below may be modified, reordered, and/or added to as best serves a particular application.
  • 1. A stimulator (140) is implanted so that its electrodes (142) and/or infusion outlet (149) are coupled to or located near a stimulation site (e.g., the occipital nerves or other nerves in the patient's head). If the stimulator (140) is a microstimulator, such as the microstimulator (200) described in FIG. 3, the microstimulator itself may be coupled to the stimulation site.
  • 2. The stimulator (140) is programmed to apply at least one stimulus to the stimulation site. The stimulus may include electrical stimulation, drug stimulation, chemical stimulation, thermal stimulation, electromagnetic stimulation, mechanical stimulation, and/or any other suitable stimulation.
  • 3. When the patient desires to invoke stimulation, the patient sends a command to the stimulator (140) (e.g., via a remote control) such that the stimulator (140) delivers the prescribed stimulation. The stimulator (140) may be alternatively or additionally configured to automatically apply the stimulation in response to sensed indicators of the medical condition.
  • 4. To cease stimulation, the patient may turn off the stimulator (140) (e.g., via a remote control).
  • 5. Periodically, the power source (145) of the stimulator (140) is recharged, if necessary, in accordance with Function 1 described above. As will be described below, this recharging function can be made much more efficient using the principles disclosed herein.
  • In other examples, the treatment administered by the stimulator (140), i.e., drug therapy and/or electrical stimulation, may be automatic and not controlled or invoked by the patient.
  • For the treatment of different patients, it may be desirable to modify or adjust the algorithmic functions performed by the implanted and/or external components, as well as the surgical approaches. For example, in some situations, it may be desirable to employ more than one stimulator (140), each of which could be separately controlled by means of a digital address. Multiple channels and/or multiple patterns of stimulation may thereby be used to deal with the multiple medical conditions, such as, for example, the combination of migraine with another form or forms of headache or the combination of headache with facial or other pain.
  • As shown in the example of FIG. 4, a first stimulator (140) implanted beneath the skin of the patient (208) provides a stimulus to a first location; a second stimulator (140′) provides a stimulus to a second location; and a third stimulator (140″) provides a stimulus to a third location. As mentioned earlier, the implanted devices may operate independently or may operate in a coordinated manner with other implanted devices or other devices external to the patient's body. That is, an external controller (250) may be configured to control the operation of each of the implanted devices (140, 140′, and 140″). In some embodiments, an implanted device, e.g. stimulator (140), may control, or operate under the control of, another implanted device(s), e.g. stimulator (140′) and/or stimulator (140″). Control lines (262-267) have been drawn in FIG. 4 to illustrate that the external controller (250) may communicate or provide power to any of the implanted devices (140, 140′, and 140″) and that each of the various implanted devices (140, 140′, and 140″) may communicate with and, in some instances, control any of the other implanted devices.
  • As a further example of multiple stimulators (140) operating in a coordinated manner, the first and second stimulators (140, 140′) of FIG. 4 may be configured to sense various indicators of a particular medical condition and transmit the measured information to the third stimulator (140″). The third stimulator (140″) may then use the measured information to adjust its stimulation parameters and apply stimulation to a stimulation site accordingly (e.g., to the occipital nerves). The various implanted stimulators may, in any combination, sense indicators of the medical condition, communicate or receive data on such indicators, and adjust stimulation parameters accordingly.
  • Alternatively, the external device (250) or other external devices communicating with the external device may be configured to sense various indicators of a patient's condition. The sensed indicators can then be collected by the external device (250) for relay to one or more of the implanted stimulators or may be transmitted directly to one or more of the implanted stimulators by any of an array of external sensing devices. In either case, the stimulator, upon receiving the sensed indicator(s), may adjust stimulation parameters accordingly. In other examples, the external controller (250) may determine whether any change to stimulation parameters is needed based on the sensed indicators. The external device (250) may then signal a command to one or more of the stimulators to adjust stimulation parameters accordingly.
  • One of the difficulties that arises in using a stimulator and a lead within a patient is determining the optimal stimulation parameters for that patient, both initially and over time. In particular, it is difficult to account for lead migration. Implanted stimulators are implanted, generally, on a long-term or permanent basis. However, with time and the natural movement of the patient, a lead from an implanted stimulator tends to move away from the location where it was first implanted. For example, a simple nod of the head may cause the position of a lead that is implanted in the neck to shift positions. This tendency is known as lead migration, or simply, migration.
  • Unfortunately, as the lead moves or migrates, the stimulator may continue to operate under the same stimulation parameters and output the same stimulus. However, because the position of the stimulator and/or its lead(s) has changed due to migration, the resulting stimulation experienced by the patient will be different. This may result due to a change in tissue impedance or distance or orientation of the electrodes caused by migration relative to the stimulation site. Consequently, lead migration may render the lead unable to provide the optimal treatment with minimal power consumption that was realized when the lead was more properly positioned.
  • While efforts are made to avoid migration, adjustment in the stimulation parameters as migration occurs may compensate for the change in position and allow the stimulator to continue to provide effective treatment. Hence, a number of methods and systems will be described herein that may be used to determine the optimal stimulation parameters for a particular patient at various points in time.
  • The optimal stimulation parameters, including the optimal electrode contact configuration, may vary depending on the particular medical condition being treated, the time of day that the stimulation is to be applied, and/or the requirements of the stimulator itself. For example, the stimulation parameters may be different during the day as opposed to during the night for a particular patient. The stimulation parameters may also be configured to optimize power consumption of the stimulator. Hence, the methods and systems described herein may be used to continuously identify and select optimal stimulation parameters as best serves a particular application.
  • In some examples, as will be described in more detail below, a technique known as “current steering” may be used to determine the optimal stimulation parameters and compensate for lead migration. Current steering is also know as neuronavigation or e-trolling. As used herein and in the appended claims, the term “current steering” will be used to describe a process used to determine the optimal stimulation parameters for a particular patient.
  • To facilitate an understanding of current steering, as described herein, a number of exemplary electrode arrangements that may be used in current steering will now be described in connection with FIGS. 5A-5H. FIGS. 5A-5H illustrate a number of exemplary electrode arrangements that may be a part of a stimulating lead (141; FIG. 2) that is used to apply a stimulus at one or more stimulation sites within a patient. Each of the electrode configurations in FIGS. 5A-5H is disposed on a paddle portion (162) of the lead (141; FIG. 2). The electrodes will also be referred to herein and in the appended claims, unless otherwise specifically denoted, as “electrode contacts” or simply “contacts.”
  • The size and shape of the paddle (162), as opposed to a thin, cylindrical lead, makes it less likely that the paddle (162) will migrate or move away from the desired stimulation site once implanted. Moreover, with time, tissue naturally begins to grow around the implanted paddle (162), further securing the paddle (162) in place. The paddle (162) may be coated with drugs that encourage such tissue growth over and around the paddle (162) to hold the paddle (162) in place. As will be appreciated, the size and shape of the paddle (162) can be adjusted as best suits a particular application or implantation environment.
  • The electrode contacts (142) on the paddle (162) may be oriented on one or both side of the paddle (162) so as to direct the stimulating current to the target stimulation site. Typically, however, the contacts (142) will be arranged on one side of the paddle (162) which is then implanted in an orientation with the contacts (142) facing the tissue to be stimulated. As shown in FIGS. 5A-5H, and as will be described in more detail below, the electrode contacts (142) may be arranged in an array with a variety of configurations to facilitate different types of stimulation or provide different current steering effects.
  • For example, the stimulator (140; FIG. 2) may be configured to provide monopolar and/or multipolar electrical stimulation at a stimulation site via the electrode contacts (142). To this end, each electrode contact (142) may be selectively programmed or configured to act as an anode or as a cathode. Each electrode contact (142) may also be programmed to be “off,” i.e., not part of the circuit deliver the stimulation current. Monopolar stimulation is achieved by placing an electrode contact acting as a cathode (or anode) adjacent to or near a stimulation site, and placing an electrode of opposite polarity relatively “far away” from the stimulation site. Bipolar stimulation is achieved by placing an anode-cathode pair adjacent to or near a stimulation site. Tripolar stimulation is achieved by placing a cathode surrounded by two anodes or an anode surrounded by two cathodes adjacent to or near a stimulation site.
  • Monopolar and multipolar electrode configurations have different stimulation properties. For example, as illustrated in FIG. 6, relative current threshold values vary as a function of distance from the stimulation site for each of these electrode configurations. As used herein and in the appended claims, the term “current threshold value” will be used to refer to the minimum amount of current required to stimulate, e.g., evoke a tissue response from, a stimulation site. FIG. 6 is a graph illustrating the relative current threshold values of monopolar, bipolar, and tripolar electrode configurations as a function of distance from the stimulation site. The graph is based on a theoretical mathematical model of neural stimulation. The current threshold values are normalized by the current threshold of the monopolar configuration.
  • As shown in FIG. 6, when the stimulation site is relatively near the stimulating lead (141; FIG. 2), lower stimulation thresholds may be achieved with a properly spaced bipole or tripole electrode configuration than with a monopole electrode configuration. However, as the distance between the stimulation site and the stimulating lead (141; FIG. 2) increases, the thresholds for the bipolar and tripolar electrode configurations begin to exceed that of the monopolar electrode configuration. Thus, monopolar stimulation is often used when the stimulation site is relatively “far” from the stimulating lead (141; FIG. 2) and multipolar stimulation is often used when the stimulation site is relatively “close” to the stimulating lead (141; FIG. 2).
  • Monopolar and multipolar electrode configurations often have different stimulation localization properties. For example, a monopolar electrode configuration emits a multidirectional electrical field that may be used to stimulate a relatively general stimulation site. A multipolar electrode configuration, on the other hand, emits a more localized electrical field that is often used to stimulate a relatively specific stimulation site, and may be used to stimulate stimulation sites that have a particular orientation (e.g., a nerve).
  • Returning to FIGS. 5A-5H, the electrode contacts (142) may be made of any conducting material that will withstand and operate effectively in an implanted environment. Such materials include, for example, a conducting ceramic, conducting polymer, copper, and/or a noble or refractory metal, such as gold, silver, platinum, iridium, tantalum, titanium, titanium nitride, niobium, and/or an alloy thereof. The use of one or more of these materials in constructing the electrode contacts (142) may serve to minimize corrosion, electrolysis, and/or damage to surrounding tissues.
  • The surfaces of the electrode contacts (142) may have any of a number of properties. For example, the surfaces may be smooth or rough. A rough surface increases the actual surface area of an electrode contact and may, with some materials (e.g., platinum or iridium), increase the pseudo-capacitance of the electrode contact. An increased pseudo-capacitance may serve to minimize the risk of adverse electrical affects to a patient being treated. A rough surface may also serve to minimize lead migration.
  • Moreover, the electrode contacts (142) may have any suitable size or shape. Differently shaped electrode contacts (142) provide different current densities. For example, a round or oval electrode contact, as shown in FIGS. 5A-5H, may provide a more uniform current density than an electrode contact that is rectangular. However, the shape of the electrode contacts (142) may vary as best serves a particular application.
  • As mentioned, the electrode contacts (142) may be arranged in a variety of array configurations to facilitate different types of stimulation. FIGS. 5A-5H illustrate a number of exemplary electrode contact arrangements that may be used to provide monopolar and/or multipolar stimulation at a stimulation site. However, it will be recognized that the electrode contact arrangements shown in FIGS. 5A-5H are merely illustrative of the many different electrode contact arrangements that may be used to provide monopolar and/or multipolar stimulation at a stimulation site.
  • For example, FIG. 5A shows a first electrode contact arrangement that may be used to provide monopolar and/or multipolar stimulation at a stimulation site. The electrode contact arrangement of FIG. 5A includes a center electrode contact (142-1) surrounded by three electrode contacts (142-2,3,4) in an equilateral triangle or trigonal planar configuration. As mentioned, each of the electrode contacts (142) may be selectively configured to act as an anode or cathode. Hence, monopolar stimulation may be achieved by using, for example, the top electrode contact (142-2) and one of the bottom electrode contacts (e.g., 142-3) as an anode-cathode pair. Bipolar stimulation may be achieved by using, for example, the center electrode contact (142-1) with one of the other electrode contacts (e.g., 142-2) as an anode-cathode pair. Tripolar stimulation may be achieved by using, for example, the center electrode contacts (142-1) with two of the other electrode contacts (e.g., 142-3 and 142-4) in an anode-cathode-anode or cathode-anode-cathode configuration.
  • As illustrated in FIGS. 5A-5H, there are many possible configurations for the electrode contact array. The illustrated examples are merely exemplary and other configurations are within the scope of the principles described herein. FIG. 5B illustrates a configuration with a central electrode contact (142) and four additional electrode contacts (142) arranged in a square around the central electrode contact (142). The four additional electrode contacts (142) may be located at the corners of a square paddle lead as shown in FIG. 5B. FIG. 5C illustrated a line of four electrode contacts (142) with a line of two electrode contacts (142) both above and below the line of four, with the lines of two electrode contacts (142) each being centered with respect to the larger line of four. FIG. 5D illustrates a similar configuration only with two lines of four electrode contacts (142) arranged between the upper and lower lines of two.
  • FIG. 5E illustrates a configuration in which the electrode contacts (142) are arranged in a two-by-four rectangular array. FIG. 5F illustrates a configuration in which a line of four electrodes is disposed adjacent a line of three electrodes, both lines being centered with respect to a rectangular paddle. FIG. 5G illustrated a configuration with six electrode contacts (142) in three columns of two electrode contacts (142) each. The center column is offset vertically with respect to the two side columns. FIG. 5H illustrates a configuration in which the electrode contacts (142) are arranged in a circle or ring pattern. Each configuration illustrated and other possible configurations for the electrode contacts (142) will provide different current steering options and may be particularly well suited to treating a particular condition or patient.
  • As mentioned, current steering may be used to determine the optimal stimulation parameters for a particular patient. FIG. 7 is a flow chart illustrating an exemplary method of current steering that may be used to determine the optimal stimulation parameters for a particular patient. The steps shown in FIG. 7 are merely illustrative and may be modified, reordered, or removed as best serves a particular application. Moreover, the steps shown in FIG. 7 may be performed by a processor or the like via a set of computer readable instructions. These computer readable instructions may be constructed in any programming language, such as Java or C, for example, and stored on any medium configured to store computer readable instructions such as a flash drive, memory chip, compact disk (CD), digital versatile disc (DVD), floppy disk, or hard drive, for example.
  • As shown in FIG. 7, one or more of the electrode contacts (142; FIGS. 5A-5H) are programmed to act as anodes (step 700). One or more of the electrode contacts (142; FIGS. 5A-5H) are also programmed to act as cathodes (step 701). It is also possible that one or more of the electrode contacts are programmed to be “off.”
  • Any of the other stimulation parameters may also be adjusted (step 702). For example, the frequency, pulse width, amplitude, burst pattern (e.g., burst on time and burst off time), duty cycle or burst repeat interval, ramp on time, and/or ramp off time of the stimulation current applied by each of the electrode contacts (142; FIGS. 5A-5H) may be adjusted.
  • Once all of the electrode contacts (142; FIGS. 5A-5H) have been programmed and the other stimulation parameters adjusted, a stimulation current is generated by the stimulator (140; FIG. 2) and applied via the electrode contacts (142; FIGS. 5A-5H) (step 703). The process is repeated until it is determined that the stimulation is optimal (Yes; step 704). Exemplary methods for determining when the stimulation is optimized will be described below. In some examples, the process is repeated until all possible combinations of anode and cathode assignments are tested.
  • A number of techniques may be used to determine whether the stimulation applied by the electrode contacts (142; FIGS. 5A-5H) is optimal (step 704). In some examples, patient feedback may be used to determine the optimal stimulation parameters. For example, if the stimulation is being applied to a nerve (e.g., the greater or lesser occipital nerves) to treat chronic headache pain, the stimulation parameters may be adjusted until the patient indicates that the greatest amount of relief from the headache pain has been achieved. Alternatively, a neural response to a particular set of stimulation parameters may be measured by a recording electrode or other device. The stimulation parameters may be adjusted until an optimal neural response is measured. Any other method may be used as best serves a particular application to determine the optimal stimulation parameters.
  • The current steering method described in connection with FIG. 7 may be performed automatically with a computerized programming station or another suitable programming device. The programming device may include a self-contained hardware/software system, or it may include software running on a standard personal computer (PC). Exemplary programming devices include, but are not limited to, the clinician programming system (157; FIG. 2) and the hand held programmer (155; FIG. 2) described above. The programming device may include a transmitting coil attachment configured to communicate with the implanted stimulator (140; FIG. 2). Alternatively, the programming device may be included within the stimulator (140; FIG. 2) itself.
  • Alternatively, the current steering method may be performed manually. For example, a physician or patient may manually steer the current with the aid of a computer, hand-held programmer, joystick, or other device.
  • A simplified example of current steering will now be given in connection with FIGS. 8A-8C. FIGS. 8A-8C include the exemplary electrode arrangement of FIG. 5A. As will be described in connection with these figures, the current may be steered in a clockwise path to find the best cathode-anode combination for a particular patient.
  • A simplified example of current steering will now be given in connection with FIGS. 8A-8C. FIGS. 8A-8C include the exemplary electrode arrangement of FIG. 5A. As will be described in connection with these figures, the current may be steered in a clockwise path to find the best cathode-anode combination for a particular patient.
  • As shown in FIG. 8A, the center electrode contact (142-1) is initially programmed as an anode (+) and the top electrode contact (142-2) is initially programmed as a cathode (−). The bottom electrode contacts (142-3,4) are programmed to be off. Hence, the stimulation current flows from the center electrode contact (142-1) to the top electrode contact (142-2) and creates an electric field E1, as shown in FIG. 8A.
  • The top electrode contact (142-2) is then turned off and the bottom right electrode contact (142-4) is programmed to act as a cathode (−), as shown in FIG. 8B. The current now flows from the center electrode contact (142-1) to the bottom right electrode contact (142-4), as indicated by the arrow labeled E2.
  • The bottom right electrode contact (142-4) is then turned off and the bottom left electrode contact (142-3) is programmed to act as a cathode (−), as shown in FIG. 8C. The resulting current flow, E3, is now between the center electrode contact (142-1) and the bottom left electrode contact (142-3).
  • This process may be repeated with some or all of the other combinations of anodes and cathodes until the optimal cathode-anode configuration is found. It will be recognized that the current may be steered in any path as best serves a particular application and that other stimulation parameters (e.g., frequency, pulse width, amplitude, burst pattern (e.g., burst on time and burst off time), duty cycle or burst repeat interval, ramp on time, and/or ramp off time) may additionally or alternatively be adjusted to determine the optimal stimulation parameters for a particular application.
  • A number of alternative current steering techniques may be used in connection with the present methods and systems described herein. For example, an exemplary current steering method is disclosed in U.S. Pat. No. 6,393,325, which is incorporated herein by reference in its entirety.
  • In some examples, the current steering methods and systems described herein are used when the lead (141; FIG. 2) and stimulator (140; FIG. 2) are initially implanted within the patient to determine the initial stimulation parameters that are best suited for the particular patient. Additionally or alternatively, the current steering methods and systems described herein may be used subsequently to account for lead migration and other changes within the patient that may occur after implantation.
  • The methods and systems described herein are particularly useful in stimulating nerves within the head or neck to treat headache pain and/or other medical conditions. However, it will be recognized that the methods and systems described herein may be used to stimulate any stimulation site within the patient to treat any medical condition.
  • As mentioned, the stimulator (140; FIG. 2) may be configured to additionally or alternatively infuse one or more drugs at the stimulation site. In some examples, the one or more drugs may have charges that are attracted to or repelled by the electrode contacts acting as anodes and cathodes. For example, a drug having a positive charge may be attracted to a cathode having a negative charge and repelled by an anode having a positive charge. Hence, in some examples, a drug may be steered to a particular stimulation site by appropriately programming the electrode contacts to have positive or negative charges.
  • The preceding description has been presented only to illustrate and describe embodiments of the invention. It is not intended to be exhaustive or to limit the invention to any precise form disclosed. Many modifications and variations are possible in light of the above teaching.

Claims (20)

1. A system for treating a patient with a medical condition, said system comprising:
a lead having an array of electrode contacts each being programmable to have either a first polarity or a second polarity; and
a programming device configured to test a multiplicity of different electrode contact polarity configurations in which a programmed polarity of one or more of said electrode contacts is varied.
2. The system of claim 1, wherein said programming device is further configured to select an optimal electrode contact polarity configuration out of said multiplicity of different electrode contact polarity configurations.
3. The system of claim 2, further comprising:
a stimulator configured to apply a stimulation current to a stimulation site in accordance with one or more stimulation parameters using said optimal electrode contact polarity configuration.
4. The system of claim 3, wherein said programming device is further configured to:
test a multiplicity of different sets of said stimulation parameters;
select an optimal set of said stimulation parameters out of said multiplicity of different sets of stimulation parameters; and
signal to said stimulator to apply said stimulation current according to said optimal set of stimulation parameters;
wherein each set of said stimulation parameters comprises different values for at least one or more of a frequency, pulse width, amplitude, burst pattern, duty cycle, ramp on time, and ramp off time of said stimulation current.
5. The system of claim 3, wherein said programming device is configured to select said optimal electrode contact polarity configuration by:
signaling said stimulator to apply a stimulus to said stimulation site with each of said multiplicity of different electrode contact polarity configurations; and
selecting said optimal electrode contact polarity configuration based on at least one or more of an optimal response of said stimulation site to said stimulus and a maximum amount of relief from said medical condition from said stimulation current.
6. The system of claim 3, wherein said stimulation site comprises at least one or more of an occipital nerve and a trigeminal nerve.
7. The system of claim 3, wherein said stimulation current comprises at least one or more of a monopolar stimulation current and a multipolar stimulation current.
8. The system of claim 3, wherein said programming device is included within said stimulator.
9. The system of claim 1, wherein said medical condition comprises at least one or more of a headache, occipital neuralgia, facial pain, and Bells palsy.
10. The system of claim 1, wherein said programming device comprises at least one or more of a clinician programming system and a hand held programmer.
11. A method of using an implantable stimulator system, said method comprising:
implanting a lead in communication with a stimulation site, said lead having an array of electrode contacts disposed thereon for applying a stimulation current to said stimulation site, each electrode contact being programmable to have either a first polarity or a second polarity;
testing a multiplicity of different electrode contact polarity configurations in which a programmed polarity of one or more of said electrode contacts is varied;
selecting an optimal electrode contact polarity configuration out of said multiplicity of different electrode contact polarity configurations; and
applying said stimulation current via said optimal electrode contact polarity configuration to said stimulation site in accordance with one or more stimulation parameters.
12. The method of claim 11, further comprising:
testing a multiplicity of different sets of said stimulation parameters;
selecting an optimal set of said stimulation parameters out of said multiplicity of different sets of stimulation parameters; and
applying said stimulus to said stimulation site according to said optimal set of said stimulation parameters;
wherein each of said sets of said stimulation parameters comprises different values for at least one or more of a frequency, pulse width, amplitude, burst pattern, duty cycle, ramp on time, and ramp off time of said stimulus.
13. The method of claim 11, wherein said selecting said optimal electrode contact polarity configuration comprises:
selecting said optimal electrode contact polarity configuration based on at least one or more of an optimal response to said stimulation current by said stimulation site and a maximum amount of relief from a medical condition resulting from said stimulation current.
14. The method of claim 11, further comprising using said stimulator system to treat at least one or more of a headache, occipital neuralgia, facial pain, and Bells palsy.
15. The method of claim 11, wherein said stimulation site comprises at least one or more of an occipital nerve and a trigeminal nerve.
16. The method of claim 11, wherein said first polarity comprises an anodic polarity and said second polarity comprises a cathodic polarity.
17. The method of claim 11, wherein said stimulation current comprises at least one or more of a monopolar stimulation current and a multipolar stimulation current.
18. The method of claim 11, further comprising automatically performing said steps of testing of said multiplicity of different electrode contact polarity configurations and selecting said optimal electrode contact polarity configuration with a processor.
19. A system for treating a patient with a medical condition, said system comprising:
a lead having an array of electrode contacts disposed thereon for applying a stimulation current to a stimulation site, each electrode contact being programmable to have either a first polarity or a second polarity;
means for testing a multiplicity of different electrode contact polarity configurations in which a programmed polarity of one or more of said electrode contacts is varied;
means for selecting an optimal electrode contact polarity configuration out of said multiplicity of different electrode contact polarity configurations; and
means for applying said stimulation current via said optimal electrode contact polarity configuration to said stimulation site in accordance with one or more stimulation parameters.
20. The system of claim 19, further comprising:
means for testing a multiplicity of different sets of said stimulation parameters;
means for selecting an optimal set of said stimulation parameters out of said multiplicity of different sets of stimulation parameters; and
means for applying said stimulation current to said stimulation site according to said optimal set of said stimulation parameters;
wherein each of said sets of said stimulation parameters comprises different values for at least one or more of a frequency, pulse width, amplitude, burst pattern, duty cycle, ramp on time, and ramp off time of said stimulation current.
US11/322,788 2005-03-14 2005-12-30 Optimal electrode contact polarity configurations for implantable stimulation systems Abandoned US20070049988A1 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
US11/280,582 US7702385B2 (en) 2005-11-16 2005-11-16 Electrode contact configurations for an implantable stimulator
US11/280,620 US7920915B2 (en) 2005-11-16 2005-11-16 Implantable stimulator
US11/322,788 US20070049988A1 (en) 2005-03-14 2005-12-30 Optimal electrode contact polarity configurations for implantable stimulation systems
EP06844430A EP1948292A4 (en) 2005-11-16 2006-11-16 Implantable stimulator configured to be implanted within a patient in a pre-determined orientation
PCT/US2006/044870 WO2007059343A2 (en) 2005-11-16 2006-11-16 Implantable stimulator configured to be implanted within a patient in a pre-determined orientation
CA002626440A CA2626440A1 (en) 2005-11-16 2006-11-16 Implantable stimulator
AU2006315285A AU2006315285B2 (en) 2005-11-16 2006-11-16 Implantable stimulator configured to be implanted within a patient in a pre-determined orientation
US13/053,031 US8630705B2 (en) 2005-11-16 2011-03-21 Implantable stimulator
US14/102,388 US20140100633A1 (en) 2005-11-16 2013-12-10 Implantable stimulator

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US66170005P 2005-03-14 2005-03-14
US11/280,582 US7702385B2 (en) 2005-11-16 2005-11-16 Electrode contact configurations for an implantable stimulator
US11/280,620 US7920915B2 (en) 2005-11-16 2005-11-16 Implantable stimulator
US11/322,788 US20070049988A1 (en) 2005-03-14 2005-12-30 Optimal electrode contact polarity configurations for implantable stimulation systems

Publications (1)

Publication Number Publication Date
US20070049988A1 true US20070049988A1 (en) 2007-03-01

Family

ID=38049329

Family Applications (5)

Application Number Title Priority Date Filing Date
US11/280,620 Expired - Fee Related US7920915B2 (en) 2005-03-14 2005-11-16 Implantable stimulator
US11/280,582 Active 2027-04-25 US7702385B2 (en) 2005-03-14 2005-11-16 Electrode contact configurations for an implantable stimulator
US11/322,788 Abandoned US20070049988A1 (en) 2005-03-14 2005-12-30 Optimal electrode contact polarity configurations for implantable stimulation systems
US13/053,031 Expired - Fee Related US8630705B2 (en) 2005-11-16 2011-03-21 Implantable stimulator
US14/102,388 Abandoned US20140100633A1 (en) 2005-11-16 2013-12-10 Implantable stimulator

Family Applications Before (2)

Application Number Title Priority Date Filing Date
US11/280,620 Expired - Fee Related US7920915B2 (en) 2005-03-14 2005-11-16 Implantable stimulator
US11/280,582 Active 2027-04-25 US7702385B2 (en) 2005-03-14 2005-11-16 Electrode contact configurations for an implantable stimulator

Family Applications After (2)

Application Number Title Priority Date Filing Date
US13/053,031 Expired - Fee Related US8630705B2 (en) 2005-11-16 2011-03-21 Implantable stimulator
US14/102,388 Abandoned US20140100633A1 (en) 2005-11-16 2013-12-10 Implantable stimulator

Country Status (5)

Country Link
US (5) US7920915B2 (en)
EP (1) EP1948292A4 (en)
AU (1) AU2006315285B2 (en)
CA (1) CA2626440A1 (en)
WO (1) WO2007059343A2 (en)

Cited By (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050137651A1 (en) * 2003-11-21 2005-06-23 Litvak Leonid M. Optimizing pitch allocation in a cochlear implant
US20060074458A1 (en) * 2001-05-01 2006-04-06 Imran Mir A Digestive organ retention device
US20070156180A1 (en) * 2005-12-30 2007-07-05 Jaax Kristen N Methods and systems for treating osteoarthritis
US20080132961A1 (en) * 2006-11-30 2008-06-05 Advanced Bionics Corporation Implant tool for use with a microstimulator
US20080262566A1 (en) * 2007-04-23 2008-10-23 Boston Scientific Neuromodulation Corporation Methods and systems of treating medication overuse headache
WO2009042217A1 (en) * 2007-09-26 2009-04-02 Duke University Method of treating parkinson's disease and other movement disorders
US20090187237A1 (en) * 2004-11-17 2009-07-23 Advanced Bionics, Llc Inner Hair Cell Stimulation Model for Use by a Cochlear Implant System
WO2010006341A1 (en) * 2008-07-11 2010-01-14 Gep Technology, Inc. Apparatus and methods for minimally invasive obesity treatment
US20100168513A1 (en) * 2008-12-29 2010-07-01 Benjamin David Pless Integrated Delivery and Visualization Tool for a Neuromodulation System
US20100179616A1 (en) * 2004-12-03 2010-07-15 Advanced Bionics, Llc Outer Hair Cell Stimulation Model for the Use by an Intra-Cochlear Implant
US20100179617A1 (en) * 2009-01-15 2010-07-15 Fletcher Kellie S Approval Per Use Implanted Neurostimulator
US20100185249A1 (en) * 2009-01-22 2010-07-22 Wingeier Brett M Method and Devices for Adrenal Stimulation
US20100249885A1 (en) * 2005-01-20 2010-09-30 Boston Scientific Neuromodulation Corporation Implantable microstimulator with plastic housing and methods of manufacture and use
US20100274313A1 (en) * 2009-04-22 2010-10-28 Carl Lance Boling Implantable Neurostimulator with Integral Hermetic Electronic Enclosure, Circuit Substrate, Monolithic Feed-Through, Lead Assembly and Anchoring Mechanism
US20100331922A1 (en) * 2009-06-30 2010-12-30 Boston Scientific Neuromodulation Corporation System and method for compensating for shifting of neurostimulation leads in a patient
US20110022114A1 (en) * 2009-07-23 2011-01-27 Navarro Rosa M System and method for treating pain with peripheral and spinal neuromodulation
US7920924B2 (en) 2004-12-16 2011-04-05 Advanced Bionics, Llc Estimating flap thickness for cochlear implants
US20110106220A1 (en) * 2009-10-05 2011-05-05 The Regents Of The University Of California Extracranial implantable devices, systems and methods for the treatment of neurological disorders
US8473062B2 (en) 2008-05-01 2013-06-25 Autonomic Technologies, Inc. Method and device for the treatment of headache
US20130253610A1 (en) * 2012-03-23 2013-09-26 Boston Scientific Neuromodulation Corporation Heuristic safety net for transitioning configurations in a neural stimulation system
WO2013152316A1 (en) * 2012-04-05 2013-10-10 The Regents Of The University Of California Subcutaneous electrodes for cranial nerve stimulation
US20150321004A1 (en) * 2013-08-14 2015-11-12 Syntilla Medical LLC Implantable head mounted neurostimulation system for head pain
US9364674B2 (en) 2010-11-30 2016-06-14 Ian A. Cook Pulse generator for cranial nerve stimulation
US9533155B2 (en) 2014-08-15 2017-01-03 Axonics Modulation Technologies, Inc. Methods for determining neurostimulation electrode configurations based on neural localization
US9555246B2 (en) 2014-08-15 2017-01-31 Axonics Modulation Technologies, Inc. Electromyographic lead positioning and stimulation titration in a nerve stimulation system for treatment of overactive bladder
US20170252568A1 (en) * 2013-10-23 2017-09-07 Syntilla Medical LLC Surgical method for implantable head mounted neurostimulation system for head pain
US10092762B2 (en) 2014-08-15 2018-10-09 Axonics Modulation Technologies, Inc. Integrated electromyographic clinician programmer for use with an implantable neurostimulator
US10195433B2 (en) 2009-04-22 2019-02-05 Nevro Corp. Selective high frequency spinal cord modulation for inhibiting pain with reduced side effects, and associated systems and methods
US10238862B2 (en) 2009-10-05 2019-03-26 The Regents Of The University Of California Extracranial implantable devices, systems and methods for the treatment of medical disorders
US10258796B2 (en) 2010-11-30 2019-04-16 Nevro Corp. Extended pain relief via high frequency spinal cord modulation, and associated systems and methods
US10328256B1 (en) 2012-06-22 2019-06-25 Nevro Corp. Autonomic nervous system control via high frequency spinal cord modulation, and associated systems and methods
US10493277B2 (en) 2011-09-08 2019-12-03 Nevro Corp. Selective high frequency spinal cord modulation for inhibiting pain, including cephalic and/or total body pain with reduced side effects, and associated systems and methods
US10493275B2 (en) 2009-04-22 2019-12-03 Nevro Corp. Spinal cord modulation for inducing paresthetic and anesthetic effects, and associated systems and methods
US10556112B1 (en) 2013-11-07 2020-02-11 Nevro Corp. Spinal cord modulation for inhibiting pain via short pulse width waveforms, and associated systems and methods
US10639468B2 (en) 2009-10-05 2020-05-05 The Regents Of The University Of California Devices, systems and methods for the treatment of medical disorders
US10751536B1 (en) 2013-06-10 2020-08-25 Nevro Corp. Methods and systems for disease treatment using electrical stimulation
US10918867B2 (en) 2009-01-29 2021-02-16 Nevro Corp. Systems and methods for producing asynchronous neural responses to treat pain and/or other patient conditions
US10960215B2 (en) 2013-10-23 2021-03-30 Nuxcel, Inc. Low profile head-located neurostimulator and method of fabrication
US11273283B2 (en) 2017-12-31 2022-03-15 Neuroenhancement Lab, LLC Method and apparatus for neuroenhancement to enhance emotional response
US11318310B1 (en) 2015-10-26 2022-05-03 Nevro Corp. Neuromodulation for altering autonomic functions, and associated systems and methods
US11364361B2 (en) 2018-04-20 2022-06-21 Neuroenhancement Lab, LLC System and method for inducing sleep by transplanting mental states
US11439829B2 (en) 2019-05-24 2022-09-13 Axonics, Inc. Clinician programmer methods and systems for maintaining target operating temperatures
US11452839B2 (en) 2018-09-14 2022-09-27 Neuroenhancement Lab, LLC System and method of improving sleep
US11590352B2 (en) 2019-01-29 2023-02-28 Nevro Corp. Ramped therapeutic signals for modulating inhibitory interneurons, and associated systems and methods
US11596798B2 (en) 2016-01-25 2023-03-07 Nevro Corp Treatment of congestive heart failure with electrical stimulation, and associated systems and methods
US11717686B2 (en) 2017-12-04 2023-08-08 Neuroenhancement Lab, LLC Method and apparatus for neuroenhancement to facilitate learning and performance
US11723579B2 (en) 2017-09-19 2023-08-15 Neuroenhancement Lab, LLC Method and apparatus for neuroenhancement
US11848090B2 (en) 2019-05-24 2023-12-19 Axonics, Inc. Trainer for a neurostimulator programmer and associated methods of use with a neurostimulation system
CN117462849A (en) * 2023-12-27 2024-01-30 中国康复研究中心 Closed loop spinal cord stimulator for inducing compound action potential for spinal cord injury neuralgia

Families Citing this family (166)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10912712B2 (en) 2004-03-25 2021-02-09 The Feinstein Institutes For Medical Research Treatment of bleeding by non-invasive stimulation
US7578819B2 (en) 2005-05-16 2009-08-25 Baxano, Inc. Spinal access and neural localization
US20110190772A1 (en) 2004-10-15 2011-08-04 Vahid Saadat Powered tissue modification devices and methods
US7887538B2 (en) 2005-10-15 2011-02-15 Baxano, Inc. Methods and apparatus for tissue modification
US8430881B2 (en) 2004-10-15 2013-04-30 Baxano, Inc. Mechanical tissue modification devices and methods
US9101386B2 (en) 2004-10-15 2015-08-11 Amendia, Inc. Devices and methods for treating tissue
US8617163B2 (en) 2004-10-15 2013-12-31 Baxano Surgical, Inc. Methods, systems and devices for carpal tunnel release
US8257356B2 (en) 2004-10-15 2012-09-04 Baxano, Inc. Guidewire exchange systems to treat spinal stenosis
US8221397B2 (en) 2004-10-15 2012-07-17 Baxano, Inc. Devices and methods for tissue modification
US9247952B2 (en) 2004-10-15 2016-02-02 Amendia, Inc. Devices and methods for tissue access
US7918849B2 (en) 2004-10-15 2011-04-05 Baxano, Inc. Devices and methods for tissue access
US20100331883A1 (en) 2004-10-15 2010-12-30 Schmitz Gregory P Access and tissue modification systems and methods
US7938830B2 (en) 2004-10-15 2011-05-10 Baxano, Inc. Powered tissue modification devices and methods
US8062300B2 (en) 2006-05-04 2011-11-22 Baxano, Inc. Tissue removal with at least partially flexible devices
US8048080B2 (en) 2004-10-15 2011-11-01 Baxano, Inc. Flexible tissue rasp
US7857813B2 (en) 2006-08-29 2010-12-28 Baxano, Inc. Tissue access guidewire system and method
AU2005323463B2 (en) 2004-12-27 2009-11-19 The Feinstein Institutes For Medical Research Treating inflammatory disorders by electrical vagus nerve stimulation
US11207518B2 (en) 2004-12-27 2021-12-28 The Feinstein Institutes For Medical Research Treating inflammatory disorders by stimulation of the cholinergic anti-inflammatory pathway
US7920915B2 (en) * 2005-11-16 2011-04-05 Boston Scientific Neuromodulation Corporation Implantable stimulator
US8366712B2 (en) 2005-10-15 2013-02-05 Baxano, Inc. Multiple pathways for spinal nerve root decompression from a single access point
US8062298B2 (en) 2005-10-15 2011-11-22 Baxano, Inc. Flexible tissue removal devices and methods
US8092456B2 (en) 2005-10-15 2012-01-10 Baxano, Inc. Multiple pathways for spinal nerve root decompression from a single access point
US7729758B2 (en) * 2005-11-30 2010-06-01 Boston Scientific Neuromodulation Corporation Magnetically coupled microstimulators
GB2435834A (en) * 2006-03-06 2007-09-12 Michael Craggs Neuromodulation device for pelvic dysfunction
US7729781B2 (en) * 2006-03-16 2010-06-01 Greatbatch Ltd. High efficiency neurostimulation lead
US8380300B2 (en) 2006-04-28 2013-02-19 Medtronic, Inc. Efficacy visualization
US8306624B2 (en) * 2006-04-28 2012-11-06 Medtronic, Inc. Patient-individualized efficacy rating
US7881803B2 (en) 2006-10-18 2011-02-01 Boston Scientific Neuromodulation Corporation Multi-electrode implantable stimulator device with a single current path decoupling capacitor
US8000804B1 (en) * 2006-10-27 2011-08-16 Sandia Corporation Electrode array for neural stimulation
US8571662B2 (en) 2007-01-29 2013-10-29 Simon Fraser University Transvascular nerve stimulation apparatus and methods
US8090450B2 (en) * 2007-06-27 2012-01-03 Greatbatch Ltd. Percutaneous electrode array and system
US8131377B2 (en) * 2007-07-11 2012-03-06 Boston Scientific Neuromodulation Corporation Telemetry listening window management for an implantable medical device
US20090054955A1 (en) * 2007-08-20 2009-02-26 Kopell Brian H Systems and Methods for Treating Neurological Disorders by Light Stimulation
WO2009032363A1 (en) 2007-09-06 2009-03-12 Baxano, Inc. Method, system and apparatus for neural localization
US20110288615A1 (en) * 2007-11-26 2011-11-24 The Board Of Regents, The University Of Texas System Implantable Therapeutic Systems Including Neurostimulation Circuits, Devices, Systems and Methods
US8192436B2 (en) 2007-12-07 2012-06-05 Baxano, Inc. Tissue modification devices
US9662490B2 (en) 2008-03-31 2017-05-30 The Feinstein Institute For Medical Research Methods and systems for reducing inflammation by neuromodulation and administration of an anti-inflammatory drug
US9211409B2 (en) 2008-03-31 2015-12-15 The Feinstein Institute For Medical Research Methods and systems for reducing inflammation by neuromodulation of T-cell activity
US8398641B2 (en) 2008-07-01 2013-03-19 Baxano, Inc. Tissue modification devices and methods
US9314253B2 (en) 2008-07-01 2016-04-19 Amendia, Inc. Tissue modification devices and methods
CA2730732A1 (en) 2008-07-14 2010-01-21 Baxano, Inc. Tissue modification devices
US9351655B2 (en) 2008-09-02 2016-05-31 Boston Scientific Neuromodulation Corporation Systems, devices, and methods for electrically coupling terminals to electrodes of electrical stimulation systems
US9079031B2 (en) * 2008-09-11 2015-07-14 Trifectas Medical Corp. Method for improving functional recovery after stroke by electrical stimulation of a cranial nerve
EP2331201B1 (en) 2008-10-01 2020-04-29 Inspire Medical Systems, Inc. System for treating sleep apnea transvenously
US8630711B1 (en) 2008-10-02 2014-01-14 University Of Utah Research Foundation Systems and methods for treating disorders by selectively activating and/or blocking muscles through intrafasicular stimulation of the pudendal nerve
EP3184045B1 (en) 2008-11-19 2023-12-06 Inspire Medical Systems, Inc. System treating sleep disordered breathing
US20100137960A1 (en) 2008-12-03 2010-06-03 Boston Scientific Neuromodulation Corporation Implantable neurostimulators having reduced pocket stimulation
JP5582619B2 (en) 2009-03-13 2014-09-03 バクサノ,インク. Flexible nerve position determination device
JP2012521864A (en) 2009-03-31 2012-09-20 インスパイア・メディカル・システムズ・インコーポレイテッド Percutaneous access method in a system for treating sleep-related abnormal breathing
US9211410B2 (en) 2009-05-01 2015-12-15 Setpoint Medical Corporation Extremely low duty-cycle activation of the cholinergic anti-inflammatory pathway to treat chronic inflammation
WO2010144578A2 (en) 2009-06-09 2010-12-16 Setpoint Medical Corporation Nerve cuff with pocket for leadless stimulator
US8394102B2 (en) 2009-06-25 2013-03-12 Baxano, Inc. Surgical tools for treatment of spinal stenosis
US8224449B2 (en) * 2009-06-29 2012-07-17 Boston Scientific Neuromodulation Corporation Microstimulator with flap electrodes
US9409013B2 (en) 2009-10-20 2016-08-09 Nyxoah SA Method for controlling energy delivery as a function of degree of coupling
US9415215B2 (en) 2009-10-20 2016-08-16 Nyxoah SA Methods for treatment of sleep apnea
US8870857B2 (en) * 2009-11-05 2014-10-28 Greatbatch Ltd. Waveguide neural interface device
US9833621B2 (en) 2011-09-23 2017-12-05 Setpoint Medical Corporation Modulation of sirtuins by vagus nerve stimulation
US11051744B2 (en) 2009-11-17 2021-07-06 Setpoint Medical Corporation Closed-loop vagus nerve stimulation
CN105126248B (en) 2009-12-23 2018-06-12 赛博恩特医疗器械公司 For treating the nerve stimulation apparatus of chronic inflammation and system
US8718780B2 (en) 2010-08-13 2014-05-06 Boston Scientific Neuromodulation Corporation System for selectively performing local and radial peripheral stimulation
US8965482B2 (en) 2010-09-30 2015-02-24 Nevro Corporation Systems and methods for positioning implanted devices in a patient
US8805519B2 (en) 2010-09-30 2014-08-12 Nevro Corporation Systems and methods for detecting intrathecal penetration
CA2817589A1 (en) 2010-11-16 2012-05-24 The Board Of Trustees Of The Leland Stanford Junior University Systems and methods for treatment of dry eye
US9821159B2 (en) 2010-11-16 2017-11-21 The Board Of Trustees Of The Leland Stanford Junior University Stimulation devices and methods
WO2012068385A2 (en) 2010-11-18 2012-05-24 Medtronic, Inc. Implantable medical device with swappable headers
US20120203316A1 (en) 2011-02-08 2012-08-09 Boston Scientific Neuromodulation Corporation Leads with segmented electrodes for electrical stimulation of planar regions and methods of making and using
US9166321B2 (en) 2011-03-22 2015-10-20 Greatbatch Ltd. Thin profile stacked layer contact
BR112013025671A2 (en) * 2011-04-07 2017-12-12 Oculeve Inc stimulation methods and devices
US8996117B2 (en) 2011-04-07 2015-03-31 Greatbatch, Ltd. Arbitrary waveform generator and neural stimulation application with scalable waveform feature
US9656076B2 (en) 2011-04-07 2017-05-23 Nuvectra Corporation Arbitrary waveform generator and neural stimulation application with scalable waveform feature and charge balancing
US8874219B2 (en) 2011-04-07 2014-10-28 Greatbatch, Ltd. Arbitrary waveform generator and neural stimulation application
US8996115B2 (en) 2011-04-07 2015-03-31 Greatbatch, Ltd. Charge balancing for arbitrary waveform generator and neural stimulation application
US9980645B1 (en) * 2011-06-21 2018-05-29 Case Western Reserve University High-contact density electrode and fabrication technique for an implantable cuff design
EP2741813B1 (en) 2011-08-11 2022-03-09 Inspire Medical Systems, Inc. System for selecting a stimulation protocol based on sensed respiratory effort
US8805512B1 (en) 2011-08-30 2014-08-12 Valencia Technologies Corporation Implantable electroacupuncture device and method for reducing hypertension
US8965511B2 (en) 2011-08-30 2015-02-24 Valencia Technologies Corporation Implantable electroacupuncture system and method for reducing hypertension
US9066845B2 (en) 2012-03-06 2015-06-30 Valencia Technologies Corporation Electrode configuration for an implantable electroacupuncture device
US8996125B2 (en) 2011-09-23 2015-03-31 Valencia Technologies Corporation Implantable electroacupuncture system and method for treating cardiovascular disease
US9173811B2 (en) 2011-09-29 2015-11-03 Valencia Technologies Corporation Implantable electroacupuncture system and method for treating depression and similar mental conditions
US9198828B2 (en) 2011-09-29 2015-12-01 Valencia Technologies Corporation Implantable electroacupuncture device and method for treating depression, bipolar disorder and anxiety
AU2012313968A1 (en) 2011-09-30 2014-05-01 Adi Mashiach Apparatus and method for extending implant life using a dual power scheme
AU2012318586B2 (en) 2011-10-04 2017-06-08 Nevro Corporation Modeling positions of implanted devices in a patient
ES2728143T3 (en) 2011-11-11 2019-10-22 Univ California Transcutaneous spinal cord stimulation: non-invasive tool for locomotor circuit activation
EP2790773B1 (en) 2012-01-25 2020-10-14 Nevro Corporation Lead anchor
EP4070850A1 (en) 2012-03-05 2022-10-12 Lungpacer Medical Inc. Transvascular nerve stimulation apparatus and methods
US9364390B2 (en) 2012-03-06 2016-06-14 Valencia Technologies Corporation Implantable electroacupuncture device and method for treating obesity
US8954143B2 (en) 2012-03-06 2015-02-10 Valencia Technologies Corporation Radial feed through packaging for an implantable electroacupuncture device
US9314399B2 (en) 2012-03-06 2016-04-19 Valencia Technologies Corporation Implantable electroacupuncture system and method for treating dyslipidemia and obesity
US9433786B2 (en) 2012-03-06 2016-09-06 Valencia Technologies Corporation Implantable electroacupuncture system and method for treating Parkinson's disease and essential tremor
US9078801B2 (en) 2012-03-06 2015-07-14 Valencia Technologies Corporation Implantable electroacupuncture device and method for treating erectile dysfunction
US9089716B2 (en) 2012-03-12 2015-07-28 Valencia Technologies Corporation Circuits and methods for using a high impedance, thin, coin-cell type battery in an implantable electroacupuncture device
US8942808B2 (en) 2012-03-12 2015-01-27 Valencia Technologies Corporation Stimulation paradigm to improve blood pressure dipping in an implantable electroacupuncture device
US9327134B2 (en) 2012-03-12 2016-05-03 Valencia Technologies Corporation Implantable electroacupuncture device and method
US9827421B2 (en) 2012-03-12 2017-11-28 Valencia Technologies Corporation Methods and systems for treating a chronic low back pain condition using an implantable electroacupuncture device
US9572983B2 (en) 2012-03-26 2017-02-21 Setpoint Medical Corporation Devices and methods for modulation of bone erosion
AU2013280184B2 (en) 2012-06-21 2017-08-24 Lungpacer Medical Inc. Transvascular diaphragm pacing systems and methods of use
US9724512B2 (en) 2012-09-28 2017-08-08 Valencia Technologies Corporation Implantable electroacupuncture system and method for treating parkinson's disease and essential tremor through application of stimului at or near an acupoint on the chorea line
US9782587B2 (en) 2012-10-01 2017-10-10 Nuvectra Corporation Digital control for pulse generators
KR102244317B1 (en) * 2013-03-12 2021-04-26 발렌시아 테크놀로지스 코포레이션 Electrode configurations for an implantable electroacupuncture device
US9993642B2 (en) * 2013-03-15 2018-06-12 The Regents Of The University Of California Multi-site transcutaneous electrical stimulation of the spinal cord for facilitation of locomotion
NZ745920A (en) 2013-04-19 2020-01-31 Oculeve Inc Nasal stimulation devices and methods
US10668270B2 (en) 2013-05-06 2020-06-02 Medtronic, Inc. Substernal leadless electrical stimulation system
US10471267B2 (en) 2013-05-06 2019-11-12 Medtronic, Inc. Implantable cardioverter-defibrillator (ICD) system including substernal lead
US10556117B2 (en) 2013-05-06 2020-02-11 Medtronic, Inc. Implantable cardioverter-defibrillator (ICD) system including substernal pacing lead
US9717923B2 (en) 2013-05-06 2017-08-01 Medtronic, Inc. Implantable medical device system having implantable cardioverter-defibrillator (ICD) system and substernal leadless pacing device
US9265935B2 (en) 2013-06-28 2016-02-23 Nevro Corporation Neurological stimulation lead anchors and associated systems and methods
US10251790B2 (en) 2013-06-28 2019-04-09 Nocira, Llc Method for external ear canal pressure regulation to alleviate disorder symptoms
US9039639B2 (en) 2013-06-28 2015-05-26 Gbs Ventures Llc External ear canal pressure regulation system
US9839777B2 (en) 2013-08-14 2017-12-12 Syntilla Medical LLC Implantable neurostimulation lead for head pain
US9427566B2 (en) 2013-08-14 2016-08-30 Syntilla Medical LLC Implantable neurostimulation lead for head pain
WO2015039108A2 (en) 2013-09-16 2015-03-19 The Board Of Trustees Of The Leland Stanford Junior University Multi-element coupler for generation of electromagnetic energy
AU2014324660A1 (en) 2013-09-27 2016-04-21 The Regents Of The University Of California Engaging the cervical spinal cord circuitry to re-enable volitional control of hand function in tetraplegic subjects
US10464836B2 (en) 2013-10-10 2019-11-05 Medtronic, Inc. Hermetic conductive feedthroughs for a semiconductor wafer
US9498635B2 (en) 2013-10-16 2016-11-22 Syntilla Medical LLC Implantable head located radiofrequency coupled neurostimulation system for head pain
EP3760276B1 (en) 2013-11-22 2023-08-30 Lungpacer Medical Inc. Apparatus for assisted breathing by transvascular nerve stimulation
WO2015095233A1 (en) 2013-12-19 2015-06-25 Boston Scientific Neuromodulation Corporation Methods and systems for employing a duty cycle in electrical stimulation of patient tissue
EP3096835B1 (en) 2014-01-21 2019-08-07 Lungpacer Medical Inc. Systems for optimization of multi-electrode nerve pacing
US20160336813A1 (en) 2015-05-15 2016-11-17 NeuSpera Medical Inc. Midfield coupler
CN110289700A (en) 2014-05-18 2019-09-27 诺伊斯佩拉医疗有限公司 Midfield coupler
US9833164B2 (en) * 2014-05-30 2017-12-05 Microsoft Technology Licensing, Llc Ring-shaped skin sensor
US9981135B2 (en) * 2014-07-17 2018-05-29 Medtronic, Inc. Multi-chamber intracardiac pacing system
EP3180069B1 (en) 2014-08-17 2020-05-13 Nine Continents Medical, Inc. Miniature implatable neurostimulator system for sciatic nerves and their branches
AU2015305237B2 (en) 2014-08-21 2020-06-18 The Regents Of The University Of California Regulation of autonomic control of bladder voiding after a complete spinal cord injury
CA2959378A1 (en) 2014-08-27 2016-03-03 The Regents Of The University Of California Multi-electrode array for spinal cord epidural stimulation
US11311725B2 (en) 2014-10-24 2022-04-26 Setpoint Medical Corporation Systems and methods for stimulating and/or monitoring loci in the brain to treat inflammation and to enhance vagus nerve stimulation
WO2016126807A1 (en) 2015-02-03 2016-08-11 Setpoint Medical Corporation Apparatus and method for reminding, prompting, or alerting a patient with an implanted stimulator
CN113908438A (en) 2015-03-19 2022-01-11 启迪医疗仪器公司 Stimulation for treating sleep disordered breathing
WO2017011410A1 (en) * 2015-07-13 2017-01-19 The Regents Of The University Of California Accessing spinal network to enable respiratory function
US11298533B2 (en) 2015-08-26 2022-04-12 The Regents Of The University Of California Concerted use of noninvasive neuromodulation device with exoskeleton to enable voluntary movement and greater muscle activation when stepping in a chronically paralyzed subject
US11097122B2 (en) 2015-11-04 2021-08-24 The Regents Of The University Of California Magnetic stimulation of the spinal cord to restore control of bladder and/or bowel
JP2019503722A (en) 2015-11-17 2019-02-14 インスパイア・メディカル・システムズ・インコーポレイテッドInspire Medical Systems, Inc. Sleep breathing disorder (SDB) microstimulation treatment device
US9717917B2 (en) 2016-01-06 2017-08-01 Syntilla Medical LLC Charging system incorporating independent charging and communication with multiple implanted devices
US10596367B2 (en) 2016-01-13 2020-03-24 Setpoint Medical Corporation Systems and methods for establishing a nerve block
US11471681B2 (en) 2016-01-20 2022-10-18 Setpoint Medical Corporation Batteryless implantable microstimulators
WO2017127756A1 (en) 2016-01-20 2017-07-27 Setpoint Medical Corporation Control of vagal stimulation
US10314501B2 (en) 2016-01-20 2019-06-11 Setpoint Medical Corporation Implantable microstimulators and inductive charging systems
US10583304B2 (en) 2016-01-25 2020-03-10 Setpoint Medical Corporation Implantable neurostimulator having power control and thermal regulation and methods of use
US10252048B2 (en) 2016-02-19 2019-04-09 Oculeve, Inc. Nasal stimulation for rhinitis, nasal congestion, and ocular allergies
CN105878273B (en) * 2016-04-21 2021-01-08 武汉时代珍传医疗器械有限公司 Ear acupoint pressing bean and preparation method thereof
US10918864B2 (en) 2016-05-02 2021-02-16 Oculeve, Inc. Intranasal stimulation for treatment of meibomian gland disease and blepharitis
US10760566B2 (en) 2016-07-22 2020-09-01 Nocira, Llc Magnetically driven pressure generator
US9955882B2 (en) * 2016-08-31 2018-05-01 Medtronic Xomed, Inc. System to monitor neural integrity
WO2018106659A1 (en) * 2016-12-05 2018-06-14 Autonomic Technologies, Inc. Neurostimulators and related systems and methods
WO2018132412A1 (en) * 2017-01-10 2018-07-19 Inspire Medical Systems, Inc. Power element for an implantable medical device
EP3585335A4 (en) 2017-02-27 2020-12-30 Nocira, LLC Ear pumps
US10980999B2 (en) 2017-03-09 2021-04-20 Nevro Corp. Paddle leads and delivery tools, and associated systems and methods
US20180272138A1 (en) * 2017-03-21 2018-09-27 Boston Scientific Neuromodulation Corporation Microstimulator with Rigid Support Structure
US20180272134A1 (en) * 2017-03-21 2018-09-27 Boston Scientific Neuromodulation Corporation Microstimulator Having Body-Mounted Electrodes and Remote Electrode Leads
US10293164B2 (en) 2017-05-26 2019-05-21 Lungpacer Medical Inc. Apparatus and methods for assisted breathing by transvascular nerve stimulation
US20190001126A1 (en) 2017-06-30 2019-01-03 Lungpacer Medical Inc. Devices and methods for prevention, moderation, and/or treatment of cognitive injury
EP3974021B1 (en) 2017-06-30 2023-06-14 ONWARD Medical N.V. A system for neuromodulation
US10195429B1 (en) 2017-08-02 2019-02-05 Lungpacer Medical Inc. Systems and methods for intravascular catheter positioning and/or nerve stimulation
US10940308B2 (en) 2017-08-04 2021-03-09 Lungpacer Medical Inc. Systems and methods for trans-esophageal sympathetic ganglion recruitment
US11173307B2 (en) 2017-08-14 2021-11-16 Setpoint Medical Corporation Vagus nerve stimulation pre-screening test
EP3758793A4 (en) 2018-03-29 2021-12-08 Nevro Corp. Leads having sidewall openings, and associated systems and methods
US11260229B2 (en) 2018-09-25 2022-03-01 The Feinstein Institutes For Medical Research Methods and apparatuses for reducing bleeding via coordinated trigeminal and vagal nerve stimulation
EP3877043A4 (en) 2018-11-08 2022-08-24 Lungpacer Medical Inc. Stimulation systems and related user interfaces
EP3653256B1 (en) 2018-11-13 2022-03-30 ONWARD Medical N.V. Control system for movement reconstruction and/or restoration for a patient
EP3695878B1 (en) 2019-02-12 2023-04-19 ONWARD Medical N.V. A system for neuromodulation
US11357979B2 (en) 2019-05-16 2022-06-14 Lungpacer Medical Inc. Systems and methods for sensing and stimulation
WO2020252037A1 (en) 2019-06-12 2020-12-17 Lungpacer Medical Inc. Circuitry for medical stimulation systems
US11697027B2 (en) * 2019-10-10 2023-07-11 Medtronic, Inc. Cardiac pacing device with mechanical mode switching
US11491324B2 (en) 2019-10-16 2022-11-08 Invicta Medical, Inc. Adjustable devices for treating sleep apnea, and associated systems and methods
DE19211698T1 (en) 2019-11-27 2021-09-02 Onward Medical B.V. Neuromodulation system
CN111918506B (en) * 2020-09-30 2021-01-26 杭州未名信科科技有限公司 Connecting structure of film electrode and shell
EP4240241A1 (en) 2020-11-04 2023-09-13 Invicta Medical, Inc. Implantable electrodes with remote power delivery for treating sleep apnea, and associated systems and methods

Citations (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3449768A (en) * 1966-12-27 1969-06-17 James H Doyle Artificial sense organ
US3727616A (en) * 1971-06-15 1973-04-17 Gen Dynamics Corp Electronic system for the stimulation of biological systems
US3760984A (en) * 1971-09-29 1973-09-25 Alza Corp Osmotically powered agent dispensing device with filling means
US3845770A (en) * 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) * 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US3923426A (en) * 1974-08-15 1975-12-02 Alza Corp Electroosmotic pump and fluid dispenser including same
US3987790A (en) * 1975-10-01 1976-10-26 Alza Corporation Osmotically driven fluid dispenser
US3995631A (en) * 1971-01-13 1976-12-07 Alza Corporation Osmotic dispenser with means for dispensing active agent responsive to osmotic gradient
US4016880A (en) * 1976-03-04 1977-04-12 Alza Corporation Osmotically driven active agent dispenser
US4036228A (en) * 1975-09-11 1977-07-19 Alza Corporation Osmotic dispenser with gas generating means
US4111202A (en) * 1976-11-22 1978-09-05 Alza Corporation Osmotic system for the controlled and delivery of agent over time
US4111203A (en) * 1976-11-22 1978-09-05 Alza Corporation Osmotic system with means for improving delivery kinetics of system
US4203440A (en) * 1978-10-23 1980-05-20 Alza Corporation Device having variable volume chamber for dispensing useful agent
US4203442A (en) * 1977-08-29 1980-05-20 Alza Corporation Device for delivering drug to a fluid environment
US4210139A (en) * 1979-01-17 1980-07-01 Alza Corporation Osmotic device with compartment for governing concentration of agent dispensed from device
US4327725A (en) * 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
US4360019A (en) * 1979-02-28 1982-11-23 Andros Incorporated Implantable infusion device
US4459989A (en) * 1981-06-30 1984-07-17 Neuromed, Inc. Non-invasive multiprogrammable tissue stimulator and methods for use
US4487603A (en) * 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4612934A (en) * 1981-06-30 1986-09-23 Borkan William N Non-invasive multiprogrammable tissue stimulator
US4627850A (en) * 1983-11-02 1986-12-09 Alza Corporation Osmotic capsule
US4678408A (en) * 1984-01-06 1987-07-07 Pacesetter Infusion, Ltd. Solenoid drive apparatus for an external infusion pump
US4685903A (en) * 1984-01-06 1987-08-11 Pacesetter Infusion, Ltd. External infusion pump apparatus
US4692147A (en) * 1980-04-02 1987-09-08 Medtronic, Inc. Drug administration device
US4725852A (en) * 1985-05-09 1988-02-16 Burlington Industries, Inc. Random artificially perturbed liquid apparatus and method
US4865845A (en) * 1986-03-21 1989-09-12 Alza Corporation Release rate adjustment of osmotic or diffusional delivery devices
US5057318A (en) * 1988-12-13 1991-10-15 Alza Corporation Delivery system for beneficial agent over a broad range of rates
US5059423A (en) * 1988-12-13 1991-10-22 Alza Corporation Delivery system comprising biocompatible beneficial agent formulation
US5080653A (en) * 1990-04-16 1992-01-14 Pacesetter Infusion, Ltd. Infusion pump with dual position syringe locator
US5097122A (en) * 1990-04-16 1992-03-17 Pacesetter Infusion, Ltd. Medication infusion system having optical motion sensor to detect drive mechanism malfunction
US5112614A (en) * 1989-09-14 1992-05-12 Alza Corporation Implantable delivery dispenser
US5137727A (en) * 1991-06-12 1992-08-11 Alza Corporation Delivery device providing beneficial agent stability
US5193540A (en) * 1991-12-18 1993-03-16 Alfred E. Mann Foundation For Scientific Research Structure and method of manufacture of an implantable microstimulator
US5193539A (en) * 1991-12-18 1993-03-16 Alfred E. Mann Foundation For Scientific Research Implantable microstimulator
US5234692A (en) * 1990-07-11 1993-08-10 Alza Corporation Delivery device with a protective sleeve
US5234693A (en) * 1990-07-11 1993-08-10 Alza Corporation Delivery device with a protective sleeve
US5292344A (en) * 1992-07-10 1994-03-08 Douglas Donald D Percutaneously placed electrical gastrointestinal pacemaker stimulatory system, sensing system, and pH monitoring system, with optional delivery port
US5312439A (en) * 1991-12-12 1994-05-17 Loeb Gerald E Implantable device having an electrolytic storage electrode
US5501703A (en) * 1994-01-24 1996-03-26 Medtronic, Inc. Multichannel apparatus for epidural spinal cord stimulator
US5728396A (en) * 1996-02-02 1998-03-17 Alza Corporation Sustained delivery of leuprolide using an implantable system
US5895416A (en) * 1997-03-12 1999-04-20 Medtronic, Inc. Method and apparatus for controlling and steering an electric field
US5938688A (en) * 1997-10-22 1999-08-17 Cornell Research Foundation, Inc. Deep brain stimulation method
US5941906A (en) * 1997-10-15 1999-08-24 Medtronic, Inc. Implantable, modular tissue stimulator
US6016449A (en) * 1997-10-27 2000-01-18 Neuropace, Inc. System for treatment of neurological disorders
US6051017A (en) * 1996-02-20 2000-04-18 Advanced Bionics Corporation Implantable microstimulator and systems employing the same
US6052624A (en) * 1999-01-07 2000-04-18 Advanced Bionics Corporation Directional programming for implantable electrode arrays
US6164284A (en) * 1997-02-26 2000-12-26 Schulman; Joseph H. System of implantable devices for monitoring and/or affecting body parameters
US6185452B1 (en) * 1997-02-26 2001-02-06 Joseph H. Schulman Battery-powered patient implantable device
US6208894B1 (en) * 1997-02-26 2001-03-27 Alfred E. Mann Foundation For Scientific Research And Advanced Bionics System of implantable devices for monitoring and/or affecting body parameters
US6219580B1 (en) * 1995-04-26 2001-04-17 Advanced Bionics Corporation Multichannel cochlear prosthesis with flexible control of stimulus waveforms
US6272382B1 (en) * 1998-07-31 2001-08-07 Advanced Bionics Corporation Fully implantable cochlear implant system
US6280873B1 (en) * 1999-04-08 2001-08-28 Quallion, Llc Wound battery and method for making it
US6308101B1 (en) * 1998-07-31 2001-10-23 Advanced Bionics Corporation Fully implantable cochlear implant system
US6308102B1 (en) * 1999-09-29 2001-10-23 Stimsoft, Inc. Patient interactive neurostimulation system and method
US20010046625A1 (en) * 2000-02-02 2001-11-29 Ruth Douglas Alan Brazed ceramic seal for batteries with titanium-titanium-6A1-4V cases
US20010053476A1 (en) * 2000-04-26 2001-12-20 Alan Ruth Lithium ion battery suitable for hybrid electric vehicles
US6368315B1 (en) * 1999-06-23 2002-04-09 Durect Corporation Composite drug delivery catheter
US6381496B1 (en) * 1999-10-01 2002-04-30 Advanced Bionics Corporation Parameter context switching for an implanted device
US6393325B1 (en) * 1999-01-07 2002-05-21 Advanced Bionics Corporation Directional programming for implantable electrode arrays
US6458171B1 (en) * 1999-04-16 2002-10-01 Quallion Llc Battery tab attachment method
US6487446B1 (en) * 2000-09-26 2002-11-26 Medtronic, Inc. Method and system for spinal cord stimulation prior to and during a medical procedure
US6505075B1 (en) * 1999-05-29 2003-01-07 Richard L. Weiner Peripheral nerve stimulation method
US6516227B1 (en) * 1999-07-27 2003-02-04 Advanced Bionics Corporation Rechargeable spinal cord stimulator system
US6539263B1 (en) * 1999-06-11 2003-03-25 Cornell Research Foundation, Inc. Feedback mechanism for deep brain stimulation
US6553263B1 (en) * 1999-07-30 2003-04-22 Advanced Bionics Corporation Implantable pulse generators using rechargeable zero-volt technology lithium-ion batteries
US6620151B2 (en) * 2001-03-01 2003-09-16 Advanced Neuromodulation Systems, Inc. Non-constant pressure infusion pump
US6662053B2 (en) * 2000-08-17 2003-12-09 William N. Borkan Multichannel stimulator electronics and methods
US6666845B2 (en) * 2001-01-04 2003-12-23 Advanced Neuromodulation Systems, Inc. Implantable infusion pump
US6735475B1 (en) * 2001-01-30 2004-05-11 Advanced Bionics Corporation Fully implantable miniature neurostimulator for stimulation as a therapy for headache and/or facial pain
US6740072B2 (en) * 2001-09-07 2004-05-25 Medtronic Minimed, Inc. System and method for providing closed loop infusion formulation delivery
US6760626B1 (en) * 2001-08-29 2004-07-06 Birinder R. Boveja Apparatus and method for treatment of neurological and neuropsychiatric disorders using programmerless implantable pulse generator system
US6770067B2 (en) * 2001-09-07 2004-08-03 Medtronic Minimed, Inc. Infusion device and driving mechanism for same
US20040199216A1 (en) * 2003-04-02 2004-10-07 Lee Michael T. Neurostimulation therapy optimization based on a rated session log
US20050245987A1 (en) * 2002-02-04 2005-11-03 Woods Carla M Method for programming implantable device
US20050288724A1 (en) * 2001-12-21 2005-12-29 Medtronic, Inc. Dual-chamber pacemaker system for simultaneous bi-chamber pacing and sensing

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4112203A (en) * 1976-07-06 1978-09-05 The Dow Chemical Company Alkali metal/sulfur battery
US4254775A (en) * 1979-07-02 1981-03-10 Mieczyslaw Mirowski Implantable defibrillator and package therefor
JPS6024957A (en) * 1983-07-20 1985-02-07 Seiko Epson Corp Ink jet recording head and manufacture thereof
US5314458A (en) * 1990-06-01 1994-05-24 University Of Michigan Single channel microstimulator
US5405363A (en) * 1991-03-15 1995-04-11 Angelon Corporation Implantable cardioverter defibrillator having a smaller displacement volume
US5314451A (en) * 1993-01-15 1994-05-24 Medtronic, Inc. Replaceable battery for implantable medical device
US5782891A (en) * 1994-06-16 1998-07-21 Medtronic, Inc. Implantable ceramic enclosure for pacing, neurological, and other medical applications in the human body
EP0855927A1 (en) * 1995-11-24 1998-08-05 Advanced Bionics Corporation System and method for conditioning pelvic musculature using an implanted microstimulator
JP2000514682A (en) 1996-07-11 2000-11-07 メドトロニック・インコーポレーテッド Minimal invasive implantable device for monitoring physiological events
JP4157168B2 (en) 1997-03-27 2008-09-24 アルフレッド イー マン ファウンデーション フォア サイエンティフィック リサーチ Implantable device system for monitoring and / or acting on body parameters
US6259937B1 (en) * 1997-09-12 2001-07-10 Alfred E. Mann Foundation Implantable substrate sensor
US6024704A (en) * 1998-04-30 2000-02-15 Medtronic, Inc Implantable medical device for sensing absolute blood pressure and barometric pressure
US6011993A (en) * 1998-04-30 2000-01-04 Advanced Bionics Corporation Method of making implanted ceramic case with enhanced ceramic case strength
US6424234B1 (en) * 1998-09-18 2002-07-23 Greatbatch-Sierra, Inc. Electromagnetic interference (emi) filter and process for providing electromagnetic compatibility of an electronic device while in the presence of an electromagnetic emitter operating at the same frequency
US5948006A (en) * 1998-10-14 1999-09-07 Advanced Bionics Corporation Transcutaneous transmission patch
US6181971B1 (en) * 1998-12-09 2001-01-30 Pacesetter, Inc. Joining conductor cables and electrodes on a multi-lumen lead body
US6909917B2 (en) * 1999-01-07 2005-06-21 Advanced Bionics Corporation Implantable generator having current steering means
US6262053B1 (en) * 1999-06-23 2001-07-17 Parker Hughes Institute Melamine derivatives as potent anti-cancer agents
AU1618401A (en) * 1999-12-06 2001-06-12 Advanced Bionics Corporation Implantable device programmer
US6920359B2 (en) 2000-02-15 2005-07-19 Advanced Bionics Corporation Deep brain stimulation system for the treatment of Parkinson's Disease or other disorders
WO2003005465A1 (en) 2001-04-25 2003-01-16 Quallion, Llc Rechargeable lithium battery for tolerating discharge to zero volts
US6596439B1 (en) 2000-04-26 2003-07-22 Quallion Llc Lithium ion battery capable of being discharged to zero volts
US7236831B2 (en) * 2000-07-13 2007-06-26 Northstar Neuroscience, Inc. Methods and apparatus for effectuating a lasting change in a neural-function of a patient
US7043299B2 (en) * 2000-09-18 2006-05-09 Cameron Health, Inc. Subcutaneous implantable cardioverter-defibrillator employing a telescoping lead
US6864755B2 (en) * 2000-10-06 2005-03-08 Alfred E. Mann Institute For Biomedical Engineering At The University Of Southern California Switched reactance modulated E-class oscillator design
US6631290B1 (en) * 2000-10-25 2003-10-07 Medtronic, Inc. Multilayer ceramic electrodes for sensing cardiac depolarization signals
US6564106B2 (en) * 2000-12-13 2003-05-13 Medtronic, Inc. Thin film electrodes for sensing cardiac depolarization signals
US6622046B2 (en) * 2001-05-07 2003-09-16 Medtronic, Inc. Subcutaneous sensing feedthrough/electrode assembly
US7778711B2 (en) * 2001-08-31 2010-08-17 Bio Control Medical (B.C.M.) Ltd. Reduction of heart rate variability by parasympathetic stimulation
US6662035B2 (en) * 2001-09-13 2003-12-09 Neuropace, Inc. Implantable lead connector assembly for implantable devices and methods of using it
US7146221B2 (en) * 2001-11-16 2006-12-05 The Regents Of The University Of California Flexible electrode array for artifical vision
US6909916B2 (en) * 2001-12-20 2005-06-21 Cardiac Pacemakers, Inc. Cardiac rhythm management system with arrhythmia classification and electrode selection
US7292890B2 (en) * 2002-06-20 2007-11-06 Advanced Bionics Corporation Vagus nerve stimulation via unidirectional propagation of action potentials
EP2462983A1 (en) * 2002-06-28 2012-06-13 Boston Scientific Neuromodulation Corporation Microstimulator having self-contained power source and bi-directional telemetry system
US20040162590A1 (en) * 2002-12-19 2004-08-19 Whitehurst Todd K. Fully implantable miniature neurostimulator for intercostal nerve stimulation as a therapy for angina pectoris
US7085605B2 (en) * 2003-01-23 2006-08-01 Epic Biosonics Inc. Implantable medical assembly
US20050058701A1 (en) 2003-01-29 2005-03-17 Yossi Gross Active drug delivery in the gastrointestinal tract
US6931272B2 (en) * 2003-04-29 2005-08-16 Medtronic, Inc. Method and apparatus to monitor pulmonary edema
US6925334B1 (en) * 2003-08-04 2005-08-02 Pacesetter, Inc. Implantable medical lead having multiple, jointly insulated electrical conductors
US7450998B2 (en) 2003-11-21 2008-11-11 Alfred E. Mann Foundation For Scientific Research Method of placing an implantable device proximate to neural/muscular tissue
US7236834B2 (en) * 2003-12-19 2007-06-26 Medtronic, Inc. Electrical lead body including an in-line hermetic electronic package and implantable medical device using the same
US7555345B2 (en) * 2005-03-11 2009-06-30 Medtronic, Inc. Implantable neurostimulator device
US7920915B2 (en) * 2005-11-16 2011-04-05 Boston Scientific Neuromodulation Corporation Implantable stimulator
US7957805B2 (en) * 2005-06-01 2011-06-07 Boston Scientific Neuromodulation Corporation Implantable microstimulator with external electrodes disposed on a film substrate and methods of manufacture and use

Patent Citations (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3449768A (en) * 1966-12-27 1969-06-17 James H Doyle Artificial sense organ
US3995631A (en) * 1971-01-13 1976-12-07 Alza Corporation Osmotic dispenser with means for dispensing active agent responsive to osmotic gradient
US3727616A (en) * 1971-06-15 1973-04-17 Gen Dynamics Corp Electronic system for the stimulation of biological systems
US3760984A (en) * 1971-09-29 1973-09-25 Alza Corp Osmotically powered agent dispensing device with filling means
US3845770A (en) * 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) * 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US3923426A (en) * 1974-08-15 1975-12-02 Alza Corp Electroosmotic pump and fluid dispenser including same
US4036228A (en) * 1975-09-11 1977-07-19 Alza Corporation Osmotic dispenser with gas generating means
US3987790A (en) * 1975-10-01 1976-10-26 Alza Corporation Osmotically driven fluid dispenser
US4016880A (en) * 1976-03-04 1977-04-12 Alza Corporation Osmotically driven active agent dispenser
US4016880B1 (en) * 1976-03-04 1983-02-01
US4111202A (en) * 1976-11-22 1978-09-05 Alza Corporation Osmotic system for the controlled and delivery of agent over time
US4111203A (en) * 1976-11-22 1978-09-05 Alza Corporation Osmotic system with means for improving delivery kinetics of system
US4203442A (en) * 1977-08-29 1980-05-20 Alza Corporation Device for delivering drug to a fluid environment
US4203440A (en) * 1978-10-23 1980-05-20 Alza Corporation Device having variable volume chamber for dispensing useful agent
US4210139A (en) * 1979-01-17 1980-07-01 Alza Corporation Osmotic device with compartment for governing concentration of agent dispensed from device
US4360019A (en) * 1979-02-28 1982-11-23 Andros Incorporated Implantable infusion device
US4692147A (en) * 1980-04-02 1987-09-08 Medtronic, Inc. Drug administration device
US4327725A (en) * 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
US4459989A (en) * 1981-06-30 1984-07-17 Neuromed, Inc. Non-invasive multiprogrammable tissue stimulator and methods for use
US4612934A (en) * 1981-06-30 1986-09-23 Borkan William N Non-invasive multiprogrammable tissue stimulator
US4487603A (en) * 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4627850A (en) * 1983-11-02 1986-12-09 Alza Corporation Osmotic capsule
US4678408A (en) * 1984-01-06 1987-07-07 Pacesetter Infusion, Ltd. Solenoid drive apparatus for an external infusion pump
US4685903A (en) * 1984-01-06 1987-08-11 Pacesetter Infusion, Ltd. External infusion pump apparatus
US4725852A (en) * 1985-05-09 1988-02-16 Burlington Industries, Inc. Random artificially perturbed liquid apparatus and method
US4865845A (en) * 1986-03-21 1989-09-12 Alza Corporation Release rate adjustment of osmotic or diffusional delivery devices
US5059423A (en) * 1988-12-13 1991-10-22 Alza Corporation Delivery system comprising biocompatible beneficial agent formulation
US5057318A (en) * 1988-12-13 1991-10-15 Alza Corporation Delivery system for beneficial agent over a broad range of rates
US5112614A (en) * 1989-09-14 1992-05-12 Alza Corporation Implantable delivery dispenser
US5080653A (en) * 1990-04-16 1992-01-14 Pacesetter Infusion, Ltd. Infusion pump with dual position syringe locator
US5097122A (en) * 1990-04-16 1992-03-17 Pacesetter Infusion, Ltd. Medication infusion system having optical motion sensor to detect drive mechanism malfunction
US5234693A (en) * 1990-07-11 1993-08-10 Alza Corporation Delivery device with a protective sleeve
US5234692A (en) * 1990-07-11 1993-08-10 Alza Corporation Delivery device with a protective sleeve
US5137727A (en) * 1991-06-12 1992-08-11 Alza Corporation Delivery device providing beneficial agent stability
US5312439A (en) * 1991-12-12 1994-05-17 Loeb Gerald E Implantable device having an electrolytic storage electrode
US5405367A (en) * 1991-12-18 1995-04-11 Alfred E. Mann Foundation For Scientific Research Structure and method of manufacture of an implantable microstimulator
US5193539A (en) * 1991-12-18 1993-03-16 Alfred E. Mann Foundation For Scientific Research Implantable microstimulator
US5193540A (en) * 1991-12-18 1993-03-16 Alfred E. Mann Foundation For Scientific Research Structure and method of manufacture of an implantable microstimulator
US5292344A (en) * 1992-07-10 1994-03-08 Douglas Donald D Percutaneously placed electrical gastrointestinal pacemaker stimulatory system, sensing system, and pH monitoring system, with optional delivery port
US5501703A (en) * 1994-01-24 1996-03-26 Medtronic, Inc. Multichannel apparatus for epidural spinal cord stimulator
US6219580B1 (en) * 1995-04-26 2001-04-17 Advanced Bionics Corporation Multichannel cochlear prosthesis with flexible control of stimulus waveforms
US5728396A (en) * 1996-02-02 1998-03-17 Alza Corporation Sustained delivery of leuprolide using an implantable system
US6051017A (en) * 1996-02-20 2000-04-18 Advanced Bionics Corporation Implantable microstimulator and systems employing the same
US6214032B1 (en) * 1996-02-20 2001-04-10 Advanced Bionics Corporation System for implanting a microstimulator
US6208894B1 (en) * 1997-02-26 2001-03-27 Alfred E. Mann Foundation For Scientific Research And Advanced Bionics System of implantable devices for monitoring and/or affecting body parameters
US6164284A (en) * 1997-02-26 2000-12-26 Schulman; Joseph H. System of implantable devices for monitoring and/or affecting body parameters
US6185452B1 (en) * 1997-02-26 2001-02-06 Joseph H. Schulman Battery-powered patient implantable device
US5895416A (en) * 1997-03-12 1999-04-20 Medtronic, Inc. Method and apparatus for controlling and steering an electric field
US5941906A (en) * 1997-10-15 1999-08-24 Medtronic, Inc. Implantable, modular tissue stimulator
US5938688A (en) * 1997-10-22 1999-08-17 Cornell Research Foundation, Inc. Deep brain stimulation method
US6016449A (en) * 1997-10-27 2000-01-18 Neuropace, Inc. System for treatment of neurological disorders
US6272382B1 (en) * 1998-07-31 2001-08-07 Advanced Bionics Corporation Fully implantable cochlear implant system
US6308101B1 (en) * 1998-07-31 2001-10-23 Advanced Bionics Corporation Fully implantable cochlear implant system
US6052624A (en) * 1999-01-07 2000-04-18 Advanced Bionics Corporation Directional programming for implantable electrode arrays
US6393325B1 (en) * 1999-01-07 2002-05-21 Advanced Bionics Corporation Directional programming for implantable electrode arrays
US6280873B1 (en) * 1999-04-08 2001-08-28 Quallion, Llc Wound battery and method for making it
US6458171B1 (en) * 1999-04-16 2002-10-01 Quallion Llc Battery tab attachment method
US6505075B1 (en) * 1999-05-29 2003-01-07 Richard L. Weiner Peripheral nerve stimulation method
US6539263B1 (en) * 1999-06-11 2003-03-25 Cornell Research Foundation, Inc. Feedback mechanism for deep brain stimulation
US6368315B1 (en) * 1999-06-23 2002-04-09 Durect Corporation Composite drug delivery catheter
US6516227B1 (en) * 1999-07-27 2003-02-04 Advanced Bionics Corporation Rechargeable spinal cord stimulator system
US6553263B1 (en) * 1999-07-30 2003-04-22 Advanced Bionics Corporation Implantable pulse generators using rechargeable zero-volt technology lithium-ion batteries
US6308102B1 (en) * 1999-09-29 2001-10-23 Stimsoft, Inc. Patient interactive neurostimulation system and method
US6381496B1 (en) * 1999-10-01 2002-04-30 Advanced Bionics Corporation Parameter context switching for an implanted device
US20010046625A1 (en) * 2000-02-02 2001-11-29 Ruth Douglas Alan Brazed ceramic seal for batteries with titanium-titanium-6A1-4V cases
US20010053476A1 (en) * 2000-04-26 2001-12-20 Alan Ruth Lithium ion battery suitable for hybrid electric vehicles
US6662053B2 (en) * 2000-08-17 2003-12-09 William N. Borkan Multichannel stimulator electronics and methods
US6487446B1 (en) * 2000-09-26 2002-11-26 Medtronic, Inc. Method and system for spinal cord stimulation prior to and during a medical procedure
US6666845B2 (en) * 2001-01-04 2003-12-23 Advanced Neuromodulation Systems, Inc. Implantable infusion pump
US6735475B1 (en) * 2001-01-30 2004-05-11 Advanced Bionics Corporation Fully implantable miniature neurostimulator for stimulation as a therapy for headache and/or facial pain
US6620151B2 (en) * 2001-03-01 2003-09-16 Advanced Neuromodulation Systems, Inc. Non-constant pressure infusion pump
US6760626B1 (en) * 2001-08-29 2004-07-06 Birinder R. Boveja Apparatus and method for treatment of neurological and neuropsychiatric disorders using programmerless implantable pulse generator system
US6740072B2 (en) * 2001-09-07 2004-05-25 Medtronic Minimed, Inc. System and method for providing closed loop infusion formulation delivery
US6770067B2 (en) * 2001-09-07 2004-08-03 Medtronic Minimed, Inc. Infusion device and driving mechanism for same
US20050288724A1 (en) * 2001-12-21 2005-12-29 Medtronic, Inc. Dual-chamber pacemaker system for simultaneous bi-chamber pacing and sensing
US20050245987A1 (en) * 2002-02-04 2005-11-03 Woods Carla M Method for programming implantable device
US20040199216A1 (en) * 2003-04-02 2004-10-07 Lee Michael T. Neurostimulation therapy optimization based on a rated session log

Cited By (122)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060074458A1 (en) * 2001-05-01 2006-04-06 Imran Mir A Digestive organ retention device
US20100121412A1 (en) * 2003-11-21 2010-05-13 Advanced Bionics, Llc Optimizing Pitch Allocation in a Cochlear Implant
US20050137651A1 (en) * 2003-11-21 2005-06-23 Litvak Leonid M. Optimizing pitch allocation in a cochlear implant
US8620445B2 (en) 2003-11-21 2013-12-31 Advanced Bionics Ag Optimizing pitch allocation in a cochlear implant
US8180455B2 (en) 2003-11-21 2012-05-15 Advanced Bionics, LLV Optimizing pitch allocation in a cochlear implant
US7702396B2 (en) 2003-11-21 2010-04-20 Advanced Bionics, Llc Optimizing pitch allocation in a cochlear implant
US9393414B2 (en) 2004-11-17 2016-07-19 Advanced Bionics Ag Inner hair cell stimulation model for use by a cochlear implant system
US8615302B2 (en) 2004-11-17 2013-12-24 Advanced Bionics Ag Inner hair cell stimulation model for use by a cochlear implant system
US20090187237A1 (en) * 2004-11-17 2009-07-23 Advanced Bionics, Llc Inner Hair Cell Stimulation Model for Use by a Cochlear Implant System
US9254384B2 (en) 2004-11-17 2016-02-09 Advanced Bionics Ag Inner hair cell stimulation model for use by a cochlear implant system
US20100179616A1 (en) * 2004-12-03 2010-07-15 Advanced Bionics, Llc Outer Hair Cell Stimulation Model for the Use by an Intra-Cochlear Implant
US8121698B2 (en) 2004-12-03 2012-02-21 Advanced Bionics, Llc Outer hair cell stimulation model for the use by an intra-cochlear implant
US7920924B2 (en) 2004-12-16 2011-04-05 Advanced Bionics, Llc Estimating flap thickness for cochlear implants
US20100249885A1 (en) * 2005-01-20 2010-09-30 Boston Scientific Neuromodulation Corporation Implantable microstimulator with plastic housing and methods of manufacture and use
US7610100B2 (en) * 2005-12-30 2009-10-27 Boston Scientific Neuromodulation Corporation Methods and systems for treating osteoarthritis
US20070156180A1 (en) * 2005-12-30 2007-07-05 Jaax Kristen N Methods and systems for treating osteoarthritis
US20080132961A1 (en) * 2006-11-30 2008-06-05 Advanced Bionics Corporation Implant tool for use with a microstimulator
US7857819B2 (en) 2006-11-30 2010-12-28 Boston Scientific Neuromodulation Corporation Implant tool for use with a microstimulator
US20080262566A1 (en) * 2007-04-23 2008-10-23 Boston Scientific Neuromodulation Corporation Methods and systems of treating medication overuse headache
US9943687B2 (en) * 2007-09-26 2018-04-17 Duke University Method of treating parkinson's disease and other movement disorders
US20110184489A1 (en) * 2007-09-26 2011-07-28 Duke University Method of treating parkinson's disease and other movement disorders
WO2009042217A1 (en) * 2007-09-26 2009-04-02 Duke University Method of treating parkinson's disease and other movement disorders
US8473062B2 (en) 2008-05-01 2013-06-25 Autonomic Technologies, Inc. Method and device for the treatment of headache
US8868215B2 (en) 2008-07-11 2014-10-21 Gep Technology, Inc. Apparatus and methods for minimally invasive obesity treatment
US20110213448A1 (en) * 2008-07-11 2011-09-01 Gep Technology, Inc. Apparatus and methods for minimally invasive obesity treatment
WO2010006341A1 (en) * 2008-07-11 2010-01-14 Gep Technology, Inc. Apparatus and methods for minimally invasive obesity treatment
US9554694B2 (en) 2008-12-29 2017-01-31 Autonomic Technologies, Inc. Integrated delivery and visualization tool for a neuromodulation system
US20100168513A1 (en) * 2008-12-29 2010-07-01 Benjamin David Pless Integrated Delivery and Visualization Tool for a Neuromodulation System
US8412336B2 (en) 2008-12-29 2013-04-02 Autonomic Technologies, Inc. Integrated delivery and visualization tool for a neuromodulation system
US8781574B2 (en) 2008-12-29 2014-07-15 Autonomic Technologies, Inc. Integrated delivery and visualization tool for a neuromodulation system
US20100179617A1 (en) * 2009-01-15 2010-07-15 Fletcher Kellie S Approval Per Use Implanted Neurostimulator
US9320908B2 (en) 2009-01-15 2016-04-26 Autonomic Technologies, Inc. Approval per use implanted neurostimulator
US20100185249A1 (en) * 2009-01-22 2010-07-22 Wingeier Brett M Method and Devices for Adrenal Stimulation
US10918867B2 (en) 2009-01-29 2021-02-16 Nevro Corp. Systems and methods for producing asynchronous neural responses to treat pain and/or other patient conditions
US11883670B2 (en) 2009-01-29 2024-01-30 Nevro Corp. Systems and methods for producing asynchronous neural responses to treat pain and/or other patient conditions
US10603494B2 (en) 2009-04-22 2020-03-31 Nevro Corp. Selective high frequency spinal cord modulation for inhibiting pain with reduced side effects, and associated systems and methods
US10226626B2 (en) 2009-04-22 2019-03-12 Nevro Corp. Selective high frequency spinal cord modulation for inhibiting pain with reduced side effects, and associated systems and methods
US8886325B2 (en) 2009-04-22 2014-11-11 Autonomic Technologies, Inc. Implantable neurostimulator with integral hermetic electronic enclosure, circuit substrate, monolithic feed-through, lead assembly and anchoring mechanism
US11229792B2 (en) 2009-04-22 2022-01-25 Nevro Corp. Spinal cord modulation for inducing paresthetic and anesthetic effects, and associated systems and methods
US10471258B2 (en) 2009-04-22 2019-11-12 Nevro Corp. Selective high frequency spinal cord modulation for inhibiting pain with reduced side effects, and associated systems and methods
US10245433B2 (en) 2009-04-22 2019-04-02 Nevro Corp. Selective high frequency spinal cord modulation for inhibiting pain with reduced side effects, and associated systems and methods
US10413729B2 (en) 2009-04-22 2019-09-17 Nevro Corp. Devices for controlling high frequency spinal cord modulation for inhibiting pain, and associated systems and methods, including simplified contact selection
US8494641B2 (en) 2009-04-22 2013-07-23 Autonomic Technologies, Inc. Implantable neurostimulator with integral hermetic electronic enclosure, circuit substrate, monolithic feed-through, lead assembly and anchoring mechanism
US11786731B2 (en) 2009-04-22 2023-10-17 Nevro Corp. Selective high frequency spinal cord modulation for inhibiting pain with reduced side effects, and associated systems and methods
US10493275B2 (en) 2009-04-22 2019-12-03 Nevro Corp. Spinal cord modulation for inducing paresthetic and anesthetic effects, and associated systems and methods
US10220208B2 (en) 2009-04-22 2019-03-05 Nevro Corp. Selective high frequency spinal cord modulation for inhibiting pain with reduced side effects, and associated systems and methods
US11759638B2 (en) 2009-04-22 2023-09-19 Nevro Corp. Spinal cord modulation for inducing paresthetic and anesthetic effects, and associated systems and methods
US10220209B2 (en) 2009-04-22 2019-03-05 Nevro Corp. Selective high frequency spinal cord modulation for inhibiting pain with reduced side effects, and associated systems and methods
US10195433B2 (en) 2009-04-22 2019-02-05 Nevro Corp. Selective high frequency spinal cord modulation for inhibiting pain with reduced side effects, and associated systems and methods
US11229793B2 (en) 2009-04-22 2022-01-25 Nevro Corp. Selective high frequency spinal cord modulation for inhibiting pain with reduced side effects, and associated systems and methods
US20100274313A1 (en) * 2009-04-22 2010-10-28 Carl Lance Boling Implantable Neurostimulator with Integral Hermetic Electronic Enclosure, Circuit Substrate, Monolithic Feed-Through, Lead Assembly and Anchoring Mechanism
US10463857B2 (en) 2009-04-22 2019-11-05 Nevro Corp. Selective high frequency spinal cord modulation for inhibiting pain with reduced side effects, and associated systems and methods
US20100331922A1 (en) * 2009-06-30 2010-12-30 Boston Scientific Neuromodulation Corporation System and method for compensating for shifting of neurostimulation leads in a patient
US9345878B2 (en) 2009-06-30 2016-05-24 Boston Scientific Neuromodulation Corporation System and method for compensating for shifting of neurostimulation leads in a patient
US20110022114A1 (en) * 2009-07-23 2011-01-27 Navarro Rosa M System and method for treating pain with peripheral and spinal neuromodulation
US8452417B2 (en) * 2009-07-23 2013-05-28 Rosa M. Navarro System and method for treating pain with peripheral and spinal neuromodulation
US10238862B2 (en) 2009-10-05 2019-03-26 The Regents Of The University Of California Extracranial implantable devices, systems and methods for the treatment of medical disorders
US10639468B2 (en) 2009-10-05 2020-05-05 The Regents Of The University Of California Devices, systems and methods for the treatment of medical disorders
US9682236B2 (en) 2009-10-05 2017-06-20 The Regents Of The University Of California Devices, systems and methods for treatment of neuropsychiatric disorders
US20110106220A1 (en) * 2009-10-05 2011-05-05 The Regents Of The University Of California Extracranial implantable devices, systems and methods for the treatment of neurological disorders
US20220331581A1 (en) * 2009-10-05 2022-10-20 The Regents Of The University Of California Extracranial implantable devices, systems and methods for the treatment of neurological disorders
US9238139B2 (en) 2009-10-05 2016-01-19 The Regents Of The University Of California Devices, systems and methods for treatment of neuropsychiatric disorders
US10058704B2 (en) 2009-10-05 2018-08-28 The Regents Of The University Of California Systems, devices and methods for the treatment of neurological disorders and conditions
US9511223B2 (en) 2009-10-05 2016-12-06 The Regents Of The University Of California Extracranial implantable devices, systems and methods for the treatment of neuropsychiatric disorders
US10195435B2 (en) 2009-10-05 2019-02-05 The Regents Of The University Of California Extracranial implantable devices, systems and methods for the treatment of neuropsychiatric disorders
US9504827B2 (en) 2009-10-05 2016-11-29 The Regents Of The University Of California Systems, devices and methods for the treatment of neurological disorders and conditions
US20160317814A1 (en) * 2009-10-05 2016-11-03 The Regents Of The University Of California Extracranial implantable devices, systems and methods for the treatment of neurological disorders
US10322283B2 (en) 2009-10-05 2019-06-18 The Regents Of The University Of California Devices, systems and methods for treatment of neuropsychiatric disorders
US9364674B2 (en) 2010-11-30 2016-06-14 Ian A. Cook Pulse generator for cranial nerve stimulation
US10016601B2 (en) 2010-11-30 2018-07-10 The Regents Of The University Of California Pulse generator for cranial nerve stimulation
US10258796B2 (en) 2010-11-30 2019-04-16 Nevro Corp. Extended pain relief via high frequency spinal cord modulation, and associated systems and methods
US11298539B2 (en) 2011-09-08 2022-04-12 Nevro Corp. Selective high frequency spinal cord modulation for inhibiting pain, including cephalic and/or total body pain with reduced side effects, and associated systems and methods
US10493277B2 (en) 2011-09-08 2019-12-03 Nevro Corp. Selective high frequency spinal cord modulation for inhibiting pain, including cephalic and/or total body pain with reduced side effects, and associated systems and methods
US11883663B2 (en) 2011-09-08 2024-01-30 Nevro Corp. Selective high frequency spinal cord modulation for inhibiting pain, including cephalic and/or total body pain with reduced side effects, and associated systems and methods
US8868198B2 (en) * 2012-03-23 2014-10-21 Boston Scientific Neuromodulation Corporation Heuristic safety net for transitioning configurations in a neural stimulation system
US8918185B2 (en) 2012-03-23 2014-12-23 Boston Scientific Neuromodulation Corporation Heuristic safety net for transitioning configurations in a neural stimulation system
US20130253610A1 (en) * 2012-03-23 2013-09-26 Boston Scientific Neuromodulation Corporation Heuristic safety net for transitioning configurations in a neural stimulation system
US9517346B2 (en) 2012-03-23 2016-12-13 Boston Scientific Neromodulation Corporation Heuristic safety net for transitioning configurations in a neural stimulation system
US9352158B2 (en) 2012-03-23 2016-05-31 Boston Scientific Neuromodulation Corporation Heuristic safety net for transitioning configurations in a neural stimulation system
WO2013152316A1 (en) * 2012-04-05 2013-10-10 The Regents Of The University Of California Subcutaneous electrodes for cranial nerve stimulation
US11247057B1 (en) 2012-06-22 2022-02-15 Nevro Corp. Autonomic nervous system control via high frequency spinal cord modulation, and associated systems and methods
US10328256B1 (en) 2012-06-22 2019-06-25 Nevro Corp. Autonomic nervous system control via high frequency spinal cord modulation, and associated systems and methods
US10751536B1 (en) 2013-06-10 2020-08-25 Nevro Corp. Methods and systems for disease treatment using electrical stimulation
US9974968B2 (en) * 2013-08-14 2018-05-22 Syntilla Medical LLC Implantable head mounted neurostimulation system for head pain
US20150321004A1 (en) * 2013-08-14 2015-11-12 Syntilla Medical LLC Implantable head mounted neurostimulation system for head pain
US11623100B2 (en) 2013-10-23 2023-04-11 Shiratronics, Inc. Low profile head-located neurostimulator
US10960215B2 (en) 2013-10-23 2021-03-30 Nuxcel, Inc. Low profile head-located neurostimulator and method of fabrication
US11400302B2 (en) * 2013-10-23 2022-08-02 Shiratronics, Inc. Surgical method for implantable neurostimulation system for pain
US20170252568A1 (en) * 2013-10-23 2017-09-07 Syntilla Medical LLC Surgical method for implantable head mounted neurostimulation system for head pain
US10850112B2 (en) * 2013-10-23 2020-12-01 Nuxcel, Inc. Surgical method for implantable neurostimulation system for pain
US11357995B2 (en) 2013-10-23 2022-06-14 Shiratronics, Inc. Implantable head located radiofrequency coupled neurostimulation system for head pain
US10946205B2 (en) 2013-10-23 2021-03-16 Nuxcel, Inc. Implantable head mounted neurostimulation system for head pain
US10695571B2 (en) 2013-10-23 2020-06-30 Nuxcel, Inc. Implantable head located radiofrequency coupled neurostimulation system for head pain
US20180221664A1 (en) * 2013-10-23 2018-08-09 Syntilla Medical LLC Surgical method for implantable neurostimulation system for pain
US10258805B2 (en) * 2013-10-23 2019-04-16 Syntilla Medical, Llc Surgical method for implantable head mounted neurostimulation system for head pain
US11612756B2 (en) 2013-10-23 2023-03-28 Shiratronics, Inc. Implantable head mounted neurostimulation system for head pain
US10576286B1 (en) 2013-11-07 2020-03-03 Nevro Corp. Spinal cord modulation for inhibiting pain via short pulse width waveforms, and associated systems and methods
US10556112B1 (en) 2013-11-07 2020-02-11 Nevro Corp. Spinal cord modulation for inhibiting pain via short pulse width waveforms, and associated systems and methods
US10569089B1 (en) 2013-11-07 2020-02-25 Nevro Corp. Spinal cord modulation for inhibiting pain via short pulse width waveforms, and associated systems and methods
US11116985B2 (en) 2014-08-15 2021-09-14 Axonics, Inc. Clinician programmer for use with an implantable neurostimulation lead
US10092762B2 (en) 2014-08-15 2018-10-09 Axonics Modulation Technologies, Inc. Integrated electromyographic clinician programmer for use with an implantable neurostimulator
US10729903B2 (en) 2014-08-15 2020-08-04 Axonics Modulation Technologies, Inc. Methods for determining neurostimulation electrode configurations based on neural localization
US9855423B2 (en) 2014-08-15 2018-01-02 Axonics Modulation Technologies, Inc. Systems and methods for neurostimulation electrode configurations based on neural localization
US9533155B2 (en) 2014-08-15 2017-01-03 Axonics Modulation Technologies, Inc. Methods for determining neurostimulation electrode configurations based on neural localization
US9555246B2 (en) 2014-08-15 2017-01-31 Axonics Modulation Technologies, Inc. Electromyographic lead positioning and stimulation titration in a nerve stimulation system for treatment of overactive bladder
US9561372B2 (en) 2014-08-15 2017-02-07 Axonics Modulation Technologies, Inc. Electromyographic lead positioning and stimulation titration in a nerve stimulation system for treatment of overactive bladder
US11730411B2 (en) 2014-08-15 2023-08-22 Axonics, Inc. Methods for determining neurostimulation electrode configurations based on neural localization
US11497916B2 (en) 2014-08-15 2022-11-15 Axonics, Inc. Electromyographic lead positioning and stimulation titration in a nerve stimulation system for treatment of overactive bladder
US10406369B2 (en) 2014-08-15 2019-09-10 Axonics Modulation Technologies, Inc. Electromyographic lead positioning and stimulation titration in a nerve stimulation system for treatment of overactive bladder
US11318310B1 (en) 2015-10-26 2022-05-03 Nevro Corp. Neuromodulation for altering autonomic functions, and associated systems and methods
US11596798B2 (en) 2016-01-25 2023-03-07 Nevro Corp Treatment of congestive heart failure with electrical stimulation, and associated systems and methods
US11723579B2 (en) 2017-09-19 2023-08-15 Neuroenhancement Lab, LLC Method and apparatus for neuroenhancement
US11717686B2 (en) 2017-12-04 2023-08-08 Neuroenhancement Lab, LLC Method and apparatus for neuroenhancement to facilitate learning and performance
US11318277B2 (en) 2017-12-31 2022-05-03 Neuroenhancement Lab, LLC Method and apparatus for neuroenhancement to enhance emotional response
US11478603B2 (en) 2017-12-31 2022-10-25 Neuroenhancement Lab, LLC Method and apparatus for neuroenhancement to enhance emotional response
US11273283B2 (en) 2017-12-31 2022-03-15 Neuroenhancement Lab, LLC Method and apparatus for neuroenhancement to enhance emotional response
US11364361B2 (en) 2018-04-20 2022-06-21 Neuroenhancement Lab, LLC System and method for inducing sleep by transplanting mental states
US11452839B2 (en) 2018-09-14 2022-09-27 Neuroenhancement Lab, LLC System and method of improving sleep
US11590352B2 (en) 2019-01-29 2023-02-28 Nevro Corp. Ramped therapeutic signals for modulating inhibitory interneurons, and associated systems and methods
US11848090B2 (en) 2019-05-24 2023-12-19 Axonics, Inc. Trainer for a neurostimulator programmer and associated methods of use with a neurostimulation system
US11439829B2 (en) 2019-05-24 2022-09-13 Axonics, Inc. Clinician programmer methods and systems for maintaining target operating temperatures
CN117462849A (en) * 2023-12-27 2024-01-30 中国康复研究中心 Closed loop spinal cord stimulator for inducing compound action potential for spinal cord injury neuralgia

Also Published As

Publication number Publication date
EP1948292A4 (en) 2009-08-26
US20070112404A1 (en) 2007-05-17
US20110172739A1 (en) 2011-07-14
US7920915B2 (en) 2011-04-05
WO2007059343A3 (en) 2007-10-04
US20070112403A1 (en) 2007-05-17
AU2006315285A1 (en) 2007-05-24
WO2007059343A2 (en) 2007-05-24
AU2006315285B2 (en) 2011-08-04
CA2626440A1 (en) 2007-05-24
US8630705B2 (en) 2014-01-14
US7702385B2 (en) 2010-04-20
US20140100633A1 (en) 2014-04-10
EP1948292A2 (en) 2008-07-30

Similar Documents

Publication Publication Date Title
US20070049988A1 (en) Optimal electrode contact polarity configurations for implantable stimulation systems
US10293166B2 (en) Fractionalized stimulation pulses in an implantable stimulator device
US8095219B2 (en) Stimulation of the stomach in response to sensed parameters to treat obesity
US8315704B2 (en) Stimulation of a stimulation site within the neck or head
JP5188494B2 (en) System and method using multiple timing channels for electrode adjustment during implant stimulator setup
US9375575B2 (en) Short duration pre-pulsing to reduce stimulation-evoked side-effetcs
US7769461B2 (en) Skull-mounted electrical stimulation system and method for treating patients
US9327069B2 (en) Methods and systems for treating a medical condition by promoting neural remodeling within the brain
US8515541B1 (en) Methods and systems for treating post-stroke disorders
US7848803B1 (en) Methods and systems for facilitating stimulation of one or more stimulation sites
US20060241717A1 (en) Treatment of movement disorders by extra dural motor cortex stimulation
JP2017523835A (en) Enhancement of dorsal horn stimulation using multiple electric fields
US20080262566A1 (en) Methods and systems of treating medication overuse headache
US9358393B1 (en) Stimulation methods and systems for treating an auditory dysfunction
US8401654B1 (en) Methods and systems for treating one or more effects of deafferentation
US20140067004A1 (en) Methods and systems for treating seizures caused by brain stimulation

Legal Events

Date Code Title Description
AS Assignment

Owner name: ADVANCED BIONICS CORPORATION, CALIFORNIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:CARBUNARU, RAFAEL;JAAX, KRISTEN N.;WHITEHURST, TODD K.;AND OTHERS;REEL/FRAME:019408/0696;SIGNING DATES FROM 20060105 TO 20060125

AS Assignment

Owner name: BOSTON SCIENTIFIC NEUROMODULATION CORPORATION, CAL

Free format text: CHANGE OF NAME;ASSIGNOR:ADVANCED BIONICS CORPORATION;REEL/FRAME:020405/0722

Effective date: 20071116

Owner name: BOSTON SCIENTIFIC NEUROMODULATION CORPORATION,CALI

Free format text: CHANGE OF NAME;ASSIGNOR:ADVANCED BIONICS CORPORATION;REEL/FRAME:020405/0722

Effective date: 20071116

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION